
==== Front
Curr Neuropharmacol
Curr Neuropharmacol
CN
Current Neuropharmacology
1570-159X
1875-6190
Bentham Science Publishers

37921169
CN-22-1960
10.2174/1570159X22999231024140544
Medicine, Neurology, Pharmacology, Neuroscience
Targeting the Main Sources of Reactive Oxygen Species Production: Possible Therapeutic Implications in Chronic Pain
Cheng Peng-Fei 1
Yuan-He 1
Ge Meng-Meng 2
Ye Da-Wei 3*
Chen Jian-Ping 4*
Wang Jin-Xi 1*
1 Division of Colorectal Surgery, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China;
2 Department of Anesthesiology and Pain Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China;
3 Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China;
4 Department of Pain Management, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, China
* Address correspondence to these authors at the Division of Colorectal Surgery, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China; E-mail: tywjx163@sxmu.edu.cn; Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China; E-mail: yedawei@hust.edu.cn; and Department of Pain Management, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, China; E-mail: JPchen22@sxmu.edu.cn
25 10 2023
2024
22 12 19601985
30 3 2023
23 8 2023
25 8 2023
© 2024 The Author(s). Published by Bentham Science Publishers
2024
The Author(s)
https://creativecommons.org/licenses/by/4.0/ © 2024 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode.
Humans have long been combating chronic pain. In clinical practice, opioids are first-choice analgesics, but long-term use of these drugs can lead to serious adverse reactions. Finding new, safe and effective pain relievers that are useful treatments for chronic pain is an urgent medical need. Based on accumulating evidence from numerous studies, excess reactive oxygen species (ROS) contribute to the development and maintenance of chronic pain. Some antioxidants are potentially beneficial analgesics in the clinic, but ROS-dependent pathways are completely inhibited only by scavenging ROS directly targeting cellular or subcellular sites. Unfortunately, current antioxidant treatments do not achieve this effect. Furthermore, some antioxidants interfere with physiological redox signaling pathways and fail to reverse oxidative damage. Therefore, the key upstream processes and mechanisms of ROS production that lead to chronic pain in vivo must be identified to discover potential therapeutic targets related to the pathways that control ROS production in vivo. In this review, we summarize the sites and pathways involved in analgesia based on the three main mechanisms by which ROS are generated in vivo, discuss the preclinical evidence for the therapeutic potential of targeting these pathways in chronic pain, note the shortcomings of current research and highlight possible future research directions to provide new targets and evidence for the development of clinical analgesics.

Keywords

Reactive oxygen species
chronic pain
mitochondria
NADPH oxidase
peroxisome
analgesics
==== Body
pmc1 INTRODUCTION

Chronic pain refers to persistent or recurring pain that lasts for an extended period of time, typically exceeding 12 weeks. It affects approximately 20% of the global population and imposes a heavy economic burden amounting to about $635 billion annually [1-3]. Despite significant advancements in designing effective therapeutic pharmacological interventions, chronic pain still poses a significant unresolved healthcare issue [4-9]. Opioids, the mainstay of chronic pain management, have contributed to over 80,000 U.S. overdose deaths in 2021. Thus, new non-opioid approaches are desperately needed [10].

Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are crucial mediators in cell signaling and homeostasis [11]. In vivo, one-electron reduction of O2 results in the O2• − formation, which subsequently undergoes disproportionation catalyzed by superoxide dismutase to generate O2 and H2O2. The other fate of O2• − is to react with the endogenous production of NO to form ONOO– through a nonenzymatic process [12]. In vivo, the generation and scavenging of ROS/RNS are in a state of homeostasis. However, when this balance is disrupted, an excessive accumulation of ROS/RNS occurs, leading to oxidative/nitrosative damage to biomolecules such as lipids, DNA, monosaccharides, and proteins [13, 14]. Recent studies have highlighted the impact of ROS and RNS on neuronal activity, as well as their role in modulating pain perception and transmission [15, 16]. This review focused mainly on the role of ROS relevant to chronic pain.

Over the past 20 years, numerous studies have demonstrated that elevated ROS expression is observed in dorsal root ganglia (DRG), spinal dorsal horn (SDH), or corticolimbic brain regions in nearly all models of chronic pain [16-20], all anatomic sites that contribute to the potentiation and amplification of pain signals [21-26]. Moreover, ROS scavengers can effectively attenuate established chronic pain [27]. It is now generally accepted that ROS play a crucial role in the development and maintenance of central and peripheral sensitization. For example, ROS are involved in promoting phosphorylation levels of N-methyl-D-aspartate (NMDA) receptors, thereby heightening the transmission of excitatory signaling. Meanwhile, they suppress gamma-aminobutyric acid (GABA)-ergic interneurons by reducing synaptic GABA release or diminishing their survival [28-32]. Additionally, ROS can influence nonselective cation channel activity directly through oxidative modification of amino acids and indirectly via second messengers [33, 34]. Moreover, ROS induces neuroinflammation by activating glial cells and modulating the expression of anti-inflammatory and pro-inflammatory cytokines in the nervous system [35-40]. The activation of the NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome may also be triggered by ROS [41].

However, based on the available evidence, the nonselective antioxidants exert limited effects on chronic pain [42, 43]. Possible explanations may be that these antioxidants lack the ability to reverse established oxidative damage. Additionally, inhibition of nociceptive transmission by these antioxidants may be required in specific pain contexts. Moreover, the complexity of ROS regulation is highlighted by the crosstalk between mitochondria and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, as well as the existence of the ROS-induced ROS release mechanism [44, 45]. All of these factors contribute to the poor ability of antioxidants to address oxidative pain relief. Furthermore, physiological concentrations of ROS are necessary for the homeostasis of the intracellular environment. Therefore, targeting the three main sources of ROS, including mitochondria, NADPH oxidase and peroxisomes, is considered a more promising option for chronic pain treatment rather than directly scavenging free radicals in a broad manner [46]. We reviewed the endogenous molecular signaling pathways and sites involved in the regulation of ROS production, which are implicated in chronic pain management. Additionally, we discussed preclinical evidence aiming to identify new targets and support the development of clinical analgesics.

2 TARGETING MITOCHONDRIA FOR CHRONIC PAIN THERAPY

Mitochondria are composed of inner and outer membranes, intermembrane space, and matrix [47]. They serve as the primary site for aerobic respiration and are responsible for the production pf approximately 90% of intracellular ROS through oxidative phosphorylation [48]. Under normal conditions, the tricarboxylic acid cycle in the mitochondria matrix produces nicotinamide adenine dinucleotide and 1,5-dihydroflavin adenine dinucleotide (FADH2). These molecules donate electrons to the mitochondrial respiratory chain (MRC) on the inner membrane. Approximately 0.2-2% of these electrons leak from the MRC and interact with O2 to generate ROS (Fig. 1) [47-53].

Exposure to exogenous stimulation results in mitochondrial damage, which triggers a sharp increase in ROS generation [54]. ROS can directly attack the MRC, impairing its function and damaging mitochondrial membrane lipids and proteins, leading to membrane receptor inactivation, mitochondrial permeability transition pore opening, increased membrane permeability, and decreased membrane potential. These processes can negatively affect the oxidative phosphorylation function of mitochondria, resulting in further ROS generation. Additionally, due to the lack of protective histones and its imperfect repair system, mitochondrial DNA (mtDNA) is vulnerable to ROS attack, leading to mtDNA mutations. These changes can impact the synthesis of mtDNA-encoded proteins, increasing O2•− generation via electron leakage, thereby triggering nucleotide mutations to form a vicious cycle [55]. Overall, mitochondria are highly sensitive to ROS, and their proper functioning is essential for cellular health.

2.1 Mitochondrial Oxidative Phosphorylation in Chronic Pain

Complex I-V are components of the MRC. An elegant demonstration of the importance of MRC for chronic pain is that the defect in complex III and IV leads to ROS-dependent neuronal death in the piriform cortex, cingulate cortex, and dentate gyrus [26]. Especially, several complex I-V inhibitors dose (1, 2, 5, and 10 μg)-dependently induce pain-relieving effects in various models of chronic pain [56]. Notably, the time point of intervention, as well as the status of neuronal mitochondria, needs to be considered when applying complex inhibitors. For example, antimycin A, a complex III inhibitor, has a pro-nociceptive effect in normal animals but converts to an antinociceptive effect after paclitaxel treatment, with efficacy only before and during paclitaxel administration [57, 58]. Additionally, rotenone (a complex I inhibitor) and oligomycin (a complex V inhibitor) exhibit intensified nociceptive effects in rats with paclitaxel- or oxaliplatin-induced neuropathic pain, potentially attributed to the variations in the experimental models employed [59]. In addition, Hamblin et al. proposed that photobiotherapy specifically targets complex IV to reduce ROS levels in stressed tissues and primary cultured cortical neurons [60, 61]. In a complete Freund's adjuvant (CFA)-induced inflammatory pain model, researchers were convinced that the analgesic effect of photobiotherapy is associated with this modulation [62]. Moreover, a clinical study suggested that arginine increases platelet mitochondrial complex IV and V synthase activity and reduces ROS levels, thereby alleviating pain in children with sickle cell disease [63]. This finding may provide insights for the treatment of various chronic pain conditions involving mitochondria.

Coenzyme Q (CoQ) 10 is a key carrier for transferring electrons in the MRC to produce ATP. It exists in three interchangeable forms: ubiquinone, ubisemiquinone radical, and ubiquinol. Among them, the ubisemiquinone radical serves as the primary source of mitochondrial superoxide radicals, and a reduction in its level or the destruction of its binding site increases superoxide production by affecting reverse electron transport [49, 50]. CoQ10 is effective in alleviating fibromyalgia, trigeminal neuralgia, and statin-induced myalgia due to its capacity to reduce ROS stress levels [64-66]. In a carrageenan-induced inflammatory pain model, the combination of idebenone (CoQ10 analog) and cyclodextrin, which improved the bioavailability of idebenone, was significantly reduced the ROS levels in the spinal cord, thereby inhibiting thermal hyperalgesia and paw edema [67, 68]. In addition, plasma CoQ10 levels are a reliable marker reflecting the degree of oxidative stress in the human body [69, 70]. Considering that CoQ is widely used as an anti-aging health supplement and for alleviating conditions linked to mitochondrial dysfunction, the findings from the aforementioned preclinical study suggest that CoQ may soon be tested in clinical trials to investigate its protective effects against chronic pain [71].

Uncoupling protein (UCP) is a mitochondrial inner membrane protein, and UCP2-5 reduces the mitochondrial membrane potential (MMP) by uncoupling survival mechanisms, thus preventing mitochondria from generating excess ROS [72]. Upregulation of UCP3 inhibits oxidative stress to protect rats with occlusal interference far from muscle pain caused by masseter damage [73, 74].

Carbonic anhydrase (CA) is a zinc-containing metalloenzyme that catalyzes the reversible hydration reaction of CO2 to form bicarbonate and protons. Members of its family are localized to special cellular and subcellular sites and show tissue-specific expression. Among them, CAVA and CAVB are localized in mitochondria and are involved in the regulation of respiration rate and ROS production [75]. Excess mitochondrial CA leads to the production of many electron donors that generate a high MMP by transporting protons across the inner mitochondrial membrane, which can inhibit electron transport in complex III and prolong the half-life of CoQ radical intermediates, subsequently increasing the chance of O2• − being reduced to superoxide [76]. Micheli et al. demonstrated that mitochondrial CAVA and CAVB inhibitors 5b and 5d counteract maladaptive plasticity in glial cells and reduce oxidative stress injury due to mitochondrial dysfunction in the central nervous system (CNS). Nociceptive hypersensitivity was well suppressed in experimental animals after acute and subchronic treatment, suggesting the therapeutic and protective significance of CA inhibitors for paclitaxel-induced neuropathy [75].

FAM173B, a mitochondrial lysine-specific protein methyltransferase, is primarily localized within the mitochondrial cristae [77]. Deficiency of FAM173B reduces both maximal respiration and proton leakage by 50%, leading to decreased ROS production [78]. In vitro, human FAM173B promotes ROS formation in primary sensory neurons. In vivo, high expression of FAM173B induced by carrageenan injection increases ROS levels in spinal sensory neurons, and intrathecal injection of FAM173B antisense oligodeoxynucleotide attenuates the development of inflammatory pain. These results fully confirm that inflammatory-induced hypersensitivity depends on the regulation of ROS by FAM173B in sensory neurons. Similar results were observed in a model of neuropathic pain (NP) induced by spared nerve injury (SNI). In addition, the chronic pain-promoting effect of FAM173B is attributed to its methyltransferase activity [77], because the methyltransferase-deficient mutant human FAM173B-D94A does not extend carrageenan-induced pain behavior [77]. Finally, whole-genome sequencing in an Icelandic population showed that targeting FAM173B seems to be available, as FAM173B-deficient populations were healthy [79]. Knockout of this “pain gene” may be the fundamental solution for the pain problem that plagues humans.

2.2 Mitochondrial Quality Control Systems in Chronic Pain

Several findings from clinical research and preclinical studies from many laboratories have demonstrated that mitochondrial dysfunction may play a critical role in multiple forms of chronic pain, including NP, inflammatory pain, and morphine tolerance [19, 57, 80, 81]. For example, chemotherapy drug-induced mitochondrial dysfunction in both A- and C-fiber nociceptors of the sciatic nerve is associated with concurrent pain behaviors [57]. Mitochondria have evolved into various quality control systems, specifically mitochondrial dynamics, mitochondrial biogenesis, and mitophagy (Fig. 1) [82]. The relationships among them are bidirectional, indicating that they both change and are changed by the form-function dynamics of mitochondria. In particular, inefficient autophagy may contribute to abnormal mitochondrial function and ROS accumulation [83]. This vicious cycle of abnormal mitochondrial quality control and biomolecule regulation provides a feedforward mechanism leading to further accumulation of mitochondrial ROS. Therefore, focusing on mitochondrial quality control might be a useful approach for chronic pain treatment.

2.2.1 Mitochondrial Fission/Fusion

Mitochondria are highly active organelles that maintain their balance by segregating injured modules by fission and exchanging contents among viable mitochondria via fusion. The proteins involved in these processes are dynamic-associated protein 1 (DRP1) and mitochondrial adaptor fission 1 (FIS1), which aid in fission, and mitofusion1/2 and optic atrophy 1 protein (OPA1), which regulate fusion [84].

DRP1 is widely expressed in the CNS, particularly in the “pain-related” laminae I and II of SDH [85]. Primarily localized in the cytoplasm, DRP1 is recruited to the outer mitochondrial membrane by FIS1, Mff, MiD49 and MiD51 molecules, enriched in potential mitochondrial fission sites and forming finger-loop structures around the mitochondria, which contract and ultimately split the mitochondria in a GTPase-dependent manner [84]. DRP1-mediated excess mitochondrial splitting or fragmentation was shown to be a key factor in pathological ROS generation [86], and the DRP1-mitochondrial fragment-ROS axis is involved in the mechanism of neuronal injury in the prefrontal cortex [87], thus, it is not surprising that this protein has been implicated in nociception. Indeed, the absence of DRP1 reverses remifentanil-induced hyperalgesia by downregulating spinal NMDAR expression through the DRP1-mitochondria-ROS pathway [88]. In addition, a clinical report of patients with DRP1 gene mutations exhibiting pain insensitivity also confirmed that normal DRP1 expression may be associated with chronic pain [89]. Wrapping gp120-infused oxidized regenerated cellulose around the sciatic nerve caused NP, resulting in increased DRP1 expression in the SDH [90]. Similarly, the analgesic effect of MitoTEMPO may be partly attributed to its modulation of DRP1, as it is able to reverse the abnormally high expression of DRP1 in the DRG of chronic constriction injury (CCI) rats [91].

Moreover, DRP1 function and expression are regulated by various posttranslational modifications (e.g., phosphorylation, nitrosylation, sumoylation, etc.) [92]. 2-Bromopalmitate blocks the palmitoylation of DRP1 by inhibiting the activity of the palmitoyltransferase ZDHHC13. It was shown that 2-Bromopalmitate treatment reduces DRP1 expression, restores the balance of mitochondrial division and fusion in the spinal cord, and reduces proinflammatory cytokine expression and ROS production, and these changes were accompanied by an increase in oxaliplatin- and CFA-induced paw withdrawal threshold in rats after 2-Bromopalmitate treatment [93, 94]. These results may partially reveal the effect of DRP1 palmitoylation on oxidative stress and chronic pain.

Unexpectedly, in another study, the investigators concluded that upregulation of DRP1 in the SDH may be beneficial for pain symptoms in experimental mice, as intrathecal injection of adeno-associated virus-induced high DRP1 expression and successfully alleviated SNI-induced pain behavior. They then explored the regulation of DRP1 on mitochondrial function and ROS in the context of pain. Based on transmission electron microscopy analysis of mitochondrial ultrastructure, they concluded that overexpression of DRP1 significantly ameliorated SNI-induced changes in vesicle parameters. In addition, DRP1-mediated ROS expression is bidirectional, as knockdown or overexpression of DRP1 up- or downregulates ROS expression levels, respectively [95].

2.2.2 Mitochondrial Biogenesis

Mitochondrial biogenesis is the process by which new mitochondria are generated from existing mitochondria, and it has been proven to promote the recovery of mitochondrial function. This process is mainly regulated by peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1α) and mitochondrial transcription factor A (TFAM). The former coordinates mitochondrial biogenesis by acting as a coactivator of multiple transcription factors, and the latter is one of the major transcription factors involved in the induction and coordination of mitochondrial genome expression.

PGC-1α activates nuclear respiratory factor 1 (NRF1) and NRF2, which subsequently regulate TFAM translocation into the mitochondrial matrix and stimulate mitochondrial DNA replication and gene expression [96]. Its reduction is responsible for the extensive neuronal loss in the cingulate gyrus and frontal cortex [97]. In neuronal B35 cells, recombinant PGC-1α prevents the increased expression of ROS under tumor necrosis factor α (TNFα) application. In morphine-tolerant mice, PGC-1α can reduce ROS levels and increase mechanical and thermal hypersensitivity [17]. PGC-1α plays an inhibitory role in nociception, as supported by a study demonstrating that intrathecal injection of ZLN005 (a PGC-1α activator) markedly reduced ROS generation and alleviated pain behaviors in CCI mice [98]. Recently, several studies have shown that PGC-1α also has a protective effect against sciatic nerve ligation (SNL) and paclitaxel-induced NP [99, 100].

NRF2 is a transcription factor that regulates the expression of genes involved in antioxidant defense and detoxification. Its activation proviedes benefits in chronic pain primarily through the alleviation of ROS-associated pathological processes [101,102]. Recently, it was found that NRF2 can directly regulate PGC-1α expression and participate in mitochondrial biogenesis [103]. The therapeutic potential of strategies targeting NRF2 was tested in CCI rats by intrathecal injections of RTA-408 (an NRF2 activator). RTA-408 restored mitochondrial bioenergetics and suppressed oxidative stress, which is the key mechanism of the analgesic effect of RTA-408 [98]. Unsurprisingly, pretreatment with either trigonelline (an NRF2 inhibitor) or SR-18292 (a PGC-1α inhibitor) completely prevented the alleviating effect of RTA-408 [98]. Approaches targeting the newly discovered role of NRF2 to develop strategies that target mitochondrial biogenesis are encouraging therapeutic options for chronic pain.

Monoamine oxidases (MAOs) includes two isoforms. MAO-A is responsible for the oxidative deamination of 5-hydroxytryptamine (5-HT) and norepinephrine while MAO-B has a major affinity for benzylamine and phenylethylamine. It is anchored to the outer mitochondrial membrane by a transmembrane helical structure located in the carboxy-terminal structural domain and is considered to be the main producer of mitochondrial ROS [104]. Studies have shown that KDS2010 (an MAO-B inhibitor) exerts similar antinociceptive effects as the ROS scavenger phenyl-N-tert-butylnitrone (PBN) in paclitaxel-induced NP. Furthermore, researchers have found that KDS2010 partially restores the weakened inhibitory GABA synaptic transmission in the spinal cord of mice treated with paclitaxel. Additionally, KDS2010 exhibits a similar effect as PBN in terms of restoring the frequency of spontaneous inhibitory postsynaptic currents (sIPSCs), suggesting that KDS2010 may restore sIPSCs frequency by targeting ROS. These findings provide evidence supporting the hypothesis that KDS2010 acts on ROS-GABA synaptic transmission to alleviate the paclitaxel-induced NP [105]. Furthermore, it has been found that elevated levels of 5-HT and norepinephrine in the thalamus and prefrontal cortex have shown promising results in relieving symptoms of fibromyalgia [106]. These effects could be attributed, at least in part, to the regulation of PGC-1α. Evidence suggests that SR-18292 (a PGC-1α inhibitor) partially abolished the analgesic effects of lasmiditan (a 5-HT agonist) and formoterol (a β2-adrenoreceptor agonist) [99, 100]. All these results indicate that the potential efficacy of MAOs in treating chronic pain is related to ROS generation via enzymatic reactions or via alterations in the levels of MAO substrates. It is worth mentioning that activation of β-adrenergic receptors in SDH neurons increases the cAMP contents in these neurons [107]. The elevation of cAMP triggers a cascade of reactions that activate cAMP-response element-binding protein (CREB) in SDH neurons [108]. This activation is closely associated with the development of cancer-induced bone pain [109]. Additionally, CREB play a significant role in the transmission of HIVgp120-induced neuropathic pain through the cytoplasmic polyadenylation element-binding protein-ROS-CREB binding protein signaling pathway [110]. Furthermore, the U.S. Food and Drug Administration has approved 5-HT receptor agonists and β2-adrenoreceptor agonists for the clinical treatment of migraine and asthma, respectively [111, 112]. These drugs may quickly be entered into clinical trials investigating their protective effects against chronic pain.

2.2.3 Mitophagy

Mitophagy is the targeted phagocytosis of damaged mitochondria by the cellular autophagic apparatus [113]. Parkin protein is recruited to damaged mitochondria and acts as a ubiquitin ligase to mediate mitochondrial autophagy.

P53 is a well-known tumor suppressor gene. Recent studies have found that in isolated cortical neurons, the p53 protein can negatively regulate the expression level of the parkin protein and subsequently impact the autophagy processes [114]. Next, Yamashita et al. investigated this regulatory mechanism in the context of diabetic NP, and they showed that the levels of p53 in the DRG were significantly higher in streptozotocin (STZ)-treated rats than in wild-type animals. Rescue of low parkin expression by pifithrin-µ (a p53 inhibitor) was found to suppress ROS accumulation and attenuated mitochondrial dysfunction in DRG neurons, as well as to reduce pain hypersensitivity after STZ treatment [115]. In another study, Krukowski et al. linked CINP to p53-mediated mitochondrial destruction. They showed that the alteration in mitochondrial morphology caused by blocking the abnormal accumulation of p53 with pifithrin-µ (an inhibitor of mitochondrial binding of p53) prevents the prevention of mechanical allodynia in mice [116, 117]. In addition, pifithrin-µ interferes with the binding of HSP70 to apoptotic protease activating factor-1 and inhibits the formation of the HSP70/p53 complex, resulting in the death of tumor cells [118]. Therefore, the combination of pifithrin-µ with chemotherapeutics may be the best option for certain cancers.

Mammalian ste20-like kinase 1 (Mst1) is a member of the Ser/Thr protein kinase family. It has been demonstrated that Mst1 regulates parkin-dependent mitochondrial autophagy by Mst1 in the myocardium [119]. Recently, Huang et al. investigated the role of Mst1 in CCI mice and showed that MsT1 expression is elevated in the sciatic nerve after CCI and that small interfering RNA (siRNA)-mediated disruption of Mst1 suppresses established pain. Finally, they confirmed that Mst1 attenuates the parkin recruitment from the cytoplasm to the mitochondria in RSC96 cells in vitro [120].

2.2.4 Mitochondrial Protection

Sirtuins (SIRT) 1-7, a family of NAD+-dependent deacetylases, have been recognized for their ability to protect mitochondria by modulating oxidative stress [121]. Among them, SIRT1 and SIRT3 have received much attention for their role in chronic pain.

SIRT1 localizes in the nucleus and mediates deacetylation of PGC-1α, a key pathway that alters PGC-1α activity [122]. Activation of the SIRT1/PGC-1α signaling pathway has been associated with the dysfunction of amygdala parvalbumin interneurons [123]. Several findings have proven that activation of this pathway can reverse the characteristic changes related to the pain of several etiologies, including paclitaxel- and SNL-induced NP as well as low back pain [124-126].

SIRT3 is mainly localized in the inner mitochondrial membrane [127]. Indeed, SIRT3-deficient hippocampal and striatal neuronal cells exhibit significantly increased mitochondrial ROS, which are restored to physiological levels when SIRT3 is overexpressed [128]. These results imply the possible potential analgesic properties of SIRT3. In a diabetes model, Zhou et al. discovered that the expression of SIRT3 in the SDH was reduced on day 21 after STZ injection and found that this change was responsible for diabetic NP, as local overexpression by delivery of the lentiviral vector into the SDH suppressed established pain. To confirm the role of SIRT3 in pain mechanisms, the authors induced downregulation of SIRT3 in the intact rat SDH, which was sufficient to elicit pain-related behaviors [129]. The analgesic effect of SIRT3 is attributed to its deacetylase activity. Specifically, it reduces the acetylation of cyclophilin D and forkhead homeobox type O 3a, providing relief from pain symptoms [19, 129]. Additionally, SIRT3 undergoes posttranslational modifications involved in maintaining the pain state. Carbonylation of SIRT3 caused by lipid peroxidation decreases its deacetylase activity and disrupts metabolic balance, thereby intensifying the sensation of pain. In a carrageenan-induced inflammatory pain model, elevated levels of 4-hydroxynonenal (a product of lipid peroxidation) and SIRT3 carbonylation were observed in the spinal cord. Inhibition of lipid peroxidation resulted in reduced SIRT3 carbonylation and alleviation of pain sensitization [130]. In conclusion, these amplified automatic feedback loops regulating SIRT3 activity and the positive feedback signaling enhancing oxidative damage suggest that restoring mitochondrial SIRT3 function and upstream and downstream pathways may be an innovative approach for chronic pain treatment.

Adenosine monophosphate-activated protein kinase (AMPK) is a widely distributed serine/threonine protein kinase that exists as a heterotrimeric complex in neurons and glial cells of the central nervous system (CNS) [131]. It is a well-known inducer of autophagy. Activation of AMPK can lead to the phosphorylation and activation of Unc-51-like kinase 1, which in turn phosphorylates and activates parkin. This activation of parkin promotes the tagging of damaged mitochondria for degradation by autophagosomes. As a key regulator of mitochondrial homeostasis, AMPK also influences mitochondrial quality control by impacting mitochondrial dynamics and biogenesis [132]. Moreover, AMPK activation has been shown to suppress nuclear factor-kappa B (NF-κB) signaling through multiple mechanisms [133-135]. By inhibiting IκB kinase activity and preventing p65 subunit nuclear translocation, AMPK reduces NF-κB dependent gene transcription [135, 136]. This NF-κB inhibition can contribute to decreased ROS production, as NF-κB can induce the expression of ROS-generating enzymes [137]. As expected, the activation of NF-κB in microglia contributes to the initiation of SNI-induced pain [138]. Maixner et al. showed that in a pSNL model, AMPK activity in the SDH is reduced in the late phase of NP, i.e., 10 days postoperatively. This alteration is responsible for NP, as pharmacological activation of AMPK activity inhibits established pain. To validate the role of AMPK in the pain mechanism, the authors induced a downregulation of AMPKα in the SDH of intact rats and found that it was adequate to elicit pain-related behaviors. The authors then further clarified that AMPKα1 is the specific AMPKα isoform associated with nociceptive processing, as AMPKα1 knockout mice exhibited similar changes in pain behavior as rats with siRNA-mediated knockdown of AMPKα [139]. The pain induced by aberrant AMPKα1 expression is linked to AMPKα-mediated regulation of ROS, as the ROS scavenger PBN was found to attenuate the heightened frequencies and amplitudes of miniature excitatory postsynaptic currents (mEPSCs) in SDH induced by AMPKα1 deficiency, as well as behavioral hypersensitivity [140]. Similarly, AICAR (an AMPK activator) attenuates DRP1-mediated mitochondrial fission and blocks NLRP3 inflammasome-mediated neuroinflammation, which in turn lessens cancer-induced bone pain [141,142]. In addition, metformin (an activator of AMPK) decreases ROS production in the sciatic nerve of diabetic mice, thereby alleviating mechanical pain sensitivity. This beneficial effect may be related to the regulation of autophagy, as the expression of Beclin-1 and LC3B was found to be significantly lower in metformin-treated diabetic mice [143]. The ability of AMPK to inhibit chronic pain-induced oxidative stress affords an additional mechanism for the protective effects of metformin in diabetic patients. Consistent with this hypothesis, compound C (an AMPK blocker) attenuates mitophagy, which in turn increases the accumulation of ROS, worsening outcomes following spinal cord injury (SCI) [144].

3 TARGETING NADPH OXIDASE FOR CHRONIC PAIN THERAPY

The NADPH oxidase family, originally described in the context of neutrophils and macrophages, constitutes an important line of defense for host immune defense during respiratory outbreaks [145]. By transferring cytoplasmic NADPH-derived electrons to O2, NADPH oxidase generates ROS and transport them into the cytosol through aquaporin channels. The NADPH oxidase family members possesses six transmembrane-spanning structural domains. The catalytic subunit gp91phox (later also called NOX2) is the most important part for its role, as it contains the redox center for oxidation of NADPH and reduction of O2, as well as the binding sites for NADPH, flavin adenine dinucleotide (FAD) and heme (Fig. 2) [146]. In recent years, seven homologs of NOX2 have been successively identified in different cells, named the NOX family, of which NOX1, NOX2 and NOX4 are closely associated with chronic pain.

3.1 NOX Isoforms in Chronic Pain

NOX1 is distributed in neurons, macrophages and glial cells in the CNS and DRG [147-149]. A previous experiment using NOX1 knockout mice confirmed that NOX1 plays a pronociceptive role in morphine tolerance. Basically, it facilitates the pain produced by morphine injection [148]. High levels of NOX1 mRNA were detected in the DRG, and pharmacological inhibition or genetic deletion of NOX1 reduces pain behavior in mice with inflammatory pain [149, 150]. NOX1-derived ROS activate and induce the translocation of protein kinase C (PKC) ε to increase transient receptor potential vanilloid 1 activity in DRG neurons, promote ERK1/2-NF-κB signaling and participate in glial cell activation in the DRG and CNS [149, 151]. Furthermore, the oxidation of NMDA in the prefrontal cortex is similarly facilitated by ROS produced by NOX1 [152]. These processes have a well-recognized role in chronic pain [153].

NOX2 is expressed in spinal microglia and neurons, DRG-stationary or recruited macrophages, and damaged peripheral nerves [16, 22, 37, 154]. Upregulated expression of NOX2 mRNA and correspondingly high levels of ROS have been reported in the spinal cords of mice with sciatic nerve transection (SNT), SCI and cancer-induced bone pain, as well as in the DRG of SNI mice, and global knockout or pharmacological inhibition of NOX2 significantly suppresses established pain [16, 37, 154, 155]. Spinal NOX2-derived ROS play a role in the development of NP by affecting synaptic plasticity, particularly long-term potentiation.This is achieved through increases in GluN2B (NMDA receptor) phosphorylation and NF-κB p65 level, as well as an increase in the spontaneous excitatory postsynaptic currents (sEPSCs) frequency in laminar II neurons [22]. It also increases M1 polarization of spinal microglia/macrophages after SCI, which may involve regulation of the IL-10/microRNA155 (miR155) signaling pathway, as NOX2 depletion leads to downregulation of miR155, which may be due to increased IL-10 signaling [155]. Peripheral NOX2-dependent mechanisms may be more conducive to the maintenance of NP. In DRG, NOX2 promotes TNFα-related signaling interactions between macrophages and neurons and subsequently activates transcription factor 3 expression following peripheral nerve injury [154]. Interestingly, NOX2 deficiency does not affect macrophage recruitment to the injured DRG [154]. As these studies were conducted in a global intervention, there is still no definitive evidence regarding whether changes in the spinal cord and DRG are influenced by NOX2-dependent alterations in macrophage function at the site of injury. NOX2ds-tat did not exert similar anti-injury effects in SCI mice after pSNI [155, 156], which may have been related to using different animal models. Identifying the optimal therapeutic window is important for the control of NOX2 signaling kinetics in chronic pain, as inhibition of NOX2 by shRNA or NOX2ds-tat was found to prevent high-frequency stimulation-induced persistent mirror pain, whereas NOX2ds-tat posttreatment was ineffective in the same animals [22]. Unlike NOX1, NOX2 in macrophages does not contribute to inflammatory pain [157]. NOX2 also contributes to morphine tolerance. NOX2 knockout prevents the development of morphine tolerance in the late phase by increasing the activation of anti-inflammatory factors (IL4 and IL10) and by decreasing the formation of proinflammatory cytokines (TNFα and IL1β) [158]. Notably, complete loss of NOX2 function leads to chronic granulomatous disease [159], which may be a safety risk that must be taken with NOX2 pharmacological inhibition.

NOX4 is inducibly expressed by microglia in spinal and nonpeptidergic neurons in the DRG, as well as in injured peripheral nerves [20, 23]. It is closely associated with pain signaling in rodent models, and pain behavior is significantly attenuated in NOX4-deficient animals [20, 23]. NOX4 contributes more to NP but less to inflammatory pain and acts mainly at the lesion site in peripheral nerves [20, 160]. NOX4 knockdown was found to abolish SNI-induced degradation of the peripheral myelin proteins MPZ and PMP22, demonstrating that NOX4 maintains NP through demyelination, as evidenced by morphological analysis of injured nerves [20]. A follow-up study by the same group identified the small calcium-binding protein S100A4 as the target of NOX4-mediated oxidation [161]. NOX4 appears to play a role in both the subacute and late stages of NP, as NOX4-deficient mice exhibit a similar degree of mechanical hypersensitivity as WT mice in the first 7 days after CCI or SNI [20]. However, another study showed that targeting NOX4 should occur at an ultra-early stage after peripheral nerve injury. Post-injury treatment (1-21 days after CCI) with GKT136901 (a NOX1/4 inhibitor), which has been shown to be effective for systemic NOX4 inhibition in atherosclerotic mice [162], did not result in an improvement in nociceptive behavior [160]. In addition, the same study revealed that NOX4 deletion benefits pain symptoms in mice through inflammation control after injury [160]. Together with NOX2, MOX4 constitutes the main source of ROS in the sciatic nerve in diabetic mice [163]. Finally, the result is that the downregulation of NOX4 inhibits GABAA-γ2 and NMDAR expression in the SDH to alleviate bone cancer pain, compensating for the contribution of NOX4 to central sensitization [23, 164]. In conclusion, NOX4 is an excellent therapeutic candidate for chronic pain, but the therapeutic window for pharmacological intervention requires further exploration.

3.2 Novel Strategies Targeting the NADPH Oxidase Family and Their Therapeutic Potential in Chronic Pain

Since NADPH oxidase is the only known family of enzymes with the sole function of producing ROS, it may represent a major disease mechanism for chronic pain and a target for mechanism-based defense against oxidative damage. NOX2/NADPH oxidase activation requires six proteins, namely, NOX2, p22phox, p67phox, p40phox, p47phox, and activated Rac1 (Fig. 2) [165]. Similarly, NOX1 complex activation requires the formation of a complex between NOXO1 and NOXA1. During this process, NOXO1 acts as a scaffold for binding NOXA1 and p22phox to enhance the efficiency of the NOXA1-NOX1 interaction. The activity of NOX4 appears to correlate only with enzyme expression [166]. Despite abundant clinical and preclinical evidence for the critical role of different NOX isoforms in chronic pain, the development of their inhibitors is lagging behind [167]. Interestingly, in vitro studies have shown that p47phox and p67phox can assemble and activate the NOX1 and NOX3 complexes in place of NOXO1 and NOXA1, suggesting a common mechanism for the activation of NADPH oxidase family members. This may also explain the failure of specific inhibitors [165, 168, 169]. Strategies for attenuating NOX-derived ROS generation other than inhibition of NOX alone are needed to prevent the development of chronic pain. We realized that the absence of expression of any NOX2 complex components results in a chronic granulomatous disease phenotype [170, 171]. This fact inspired us to develop strategies to control NADPH oxidases, including a) modulating the expression of other NOX complex components and b) interfering with upstream signaling molecules [172].

3.2.1 Therapeutic Potential of Other NOX Complex Subunits in Chronic Pain

Rac1 is a Rho GTPase and is converted from an active state to an inactive state through the G protein cycle (Fig. 2) [173, 174]. In addition to acting as a direct participant, it can induce the membrane translocation of p47phox and p67phox during the activation of NADPH oxidase. In this process, the expression level of Rac1 plays a pivotal role than the integrity of the insertion domain [175]. Not surprisingly, NSC23766, a Rac1 inhibitor, was found to exert potent analgesic effects in the rat model of burn injury and paclitaxel-induced NP [176, 177].

Apurinic/apyrimidinic endonuclease 1/redox effector factor-1 (APE1/Ref-1) is widely expressed in mammalian cells and participates in DNA base excision repair and redox-sensitive transcriptional regulation. It may relocalize relying on tissue or cell type, metabolic status, and stress condition, indicating that their subcellular localization and trafficking are important for regulating function [178]. Specifically, in human umbilical vein endothelial cells, APE1/Ref-1 inhibits Rac1-induced H2O2 elevation by their extranuclear function [179]. Due to the ubiquitous distribution of APE1/Ref-1 and Rac1, their functional interaction may also be related to redox biology in other cell types. Zaky et al. reported that oxidative stress is regulated via APE1/Ref-1 in the chronic pain background. They showed that under inflammatory conditions, APE1/Ref-1 expression decreases and its nuclear accumulation increases [180]. Cotreatment with E3330 (an APE1 inhibitor) and CFA induces cytosolic translocation of APE1/Ref-1 and restores the total tissue antioxidant capacity to normal levels in the spinal cord, thereby inhibiting mechanical allodynia in mice. All these results suggested that both the expression and subcellular localization of APE1/Ref-1 for resisting oxidative stress underlying inflammatory pain [180]. Interestingly, the effect of APE1/Ref-1 in suppressing H2O2 is due to its ability to reduce H2O2 production, as overexpression of APE1/Ref-1 does not reverse the increase in cellular H2O2 levels caused by exogenous H2O2 [179]. As key upstream factors in cellular defenses against oxidative stress, APE1/Ref-1 signaling has an innate advantage in alleviating pain.

Ryanodine receptors (RyRs) are intracellular calcium channels expressed in neural tissue that mediate the rapid release of calcium ions from the endoplasmic reticulum (ER) and sarcoplasmic reticulum [181], resulting in Rac1 activation [182]. In an SCI model, genetic deletion of RyR induced the expected suppression of mechanical allodynia by inhibiting NOX2-derived ROS levels and the release of inflammatory factors in the spinal cord [183]. Interestingly, in another experiment, Wilson et al. verified the mechanism by which neuronal ROS regulate Rac1 activity through RyR-mediated Ca2+ release [184]. A feedforward loop between ROS and Rac1 is formed, and these interactions generate both an amplified automatic feedback loop that modulates RyR activity and a positive feedback loop that amplifies ROS signaling and exacerbates oxidative damage. Unfortunately, direct evidence for a feedforward mechanism in the context of chronic pain is lacking. In addition, RyR-mediated Ca2+ release triggers mitochondrial fragmentation, leading to mitochondrial ROS generation [185]. Godai et al. assessed the significance of RyR-mediated regulation of mitochondrial ROS in HIV-related NP. The authors revealed that RyR and mitochondrial superoxide levels were increased in the SDH, whereas intrathecal injection of dantrolene (a RyR antagonist) conspicuously reduced ROS levels and increased the pain threshold in rats [186].

Caveolin-1 (Cav-1) functions as a specific regulator in biological processes such as signal transduction and cell regulation beyond its role as a major structural protein for caveolae formation [187]. Specifically, it is an important mediator of Rac1/NOX-derived ROS generation [188]. Researchers quantified the expression of Rac1 and NOX2 in STZ-induced diabetes rats to verify the role of this regulatory mechanism in chronic pain. They observed that the proteins were significantly upregulated compared to controls. Subcutaneous injection of a Cav-1 inhibitor reduced NOX2 expression, thereby inhibiting NMDA receptor activation and dramatically reversing established mechanical and thermal hyperalgesia [189].p47phox acts as an important adaptor protein conveying the cytosolic complex (consisting of p47phox-p67phox-p40phox) to the plasma membrane to complete docking with cytochrome b558 (comprising gp91phox and p22phox) during NADPH oxidase activation [190]. Indeed, in the streptozotocin-induced type 1 diabetes model, p47phox and gp91phox are upregulated in the spinal cord and correlated with painful behavior [191]. Genetic approaches disrupting p47phox result in a complete attenuation of morphine tolerance [158]. In addition, p47phox might be the major mediator of C-C motif chemokine ligand 2 (CCL2)-induced oxidative stress and hyperalgesia. For the genetic polymorphism of ncf1 coding for p47phox [192], Dark Agouti rats exhibited less painful behavior in response to CCL2 than Wistar rats [157]. Intra-articular injection with p47phox siRNA-loaded poly (D, L-lactic-co-glycolic acid) nanoparticles showed fruitful internalization and significantly attenuated the oxidative stress in osteoarthritis mice cartilage [193]. NOX2ds-tat specifically targets the p47phox subunit and, as expected, their binding blocks the assembly and activation of the NOX2 complex [172], thus exerting a powerful anti-injurious effect [22, 155].

p22phox contributes to chronic pain processing. Quantitative real-time polymerase chain reaction showed that p22phox mRNA in the DRG of SNI animals was upregulated 3-14 days after surgery [154]. Studies have shown that p22phox is upregulated in the sciatic nerve of diabetic rats. This change is associated with increased ROS production and oxidative DNA damage [194]. Plasma membrane translocation of NOXO1 in nociceptive neurons induces ROS production, which develops into inflammatory pain [195]. Some preclinical studies have also indicated that curcumin and jinmaitong exert favorable analgesic effects [196]. Their ability to inhibit the NADPH oxidase subunits p22phox, p47phox and gp91phox provides an alternative mechanism for their protective effects against chronic pain [191, 194].

At present, research on the functional subunit of NOX mainly focuses on cardiovascular and cerebrovascular diseases, and research on chronic pain is still relatively rare. The physiological and pathological functions of NOX regulatory subunits in the context of chronic pain and their establishment as targets for regulating pain require more direct evidence. Moreover, natural and traditional Chinese medicine compounds generally exert pleiotropic and direct antioxidant effects. Thus, off-target screening of these compounds is required before on-target in vivo proof-of-concept studies.

3.2.2 Analgesic Potential of Targeting Pathways of NOX-derived ROS Generation

Hydrogen voltage-gated channel 1 (Hv1) regulates NOX activity by maintaining the balance of H+ current and e-current produced by NOX in the phagocyte membrane [197]. Recently, Peng et al. investigated the regulation of NOX2 by Hv1 during NP [198]. They found that the Hv1 proton channel is functionally expressed in spinal microglia and is upregulated after SNT and common peroneal nerve ligation, paralleling a critical time window for NP development. Pain behavior in Hv1 KO mice was significantly reduced compared to that in WT mice. These experimental results confirm the role of Hv1 in the mechanism of NP. Next, the authors quantified NOX2 expression and found that it was significantly lower in the spinal cords of Hv1-KO mice than in those of wild-type animals, suggesting a causal relationship. Importantly, the administration of ROS scavengers reduced mechanical allodynia induced by peripheral nerve injury in intact mice but had no effect on Hv1-KO mice. These results convincingly suggest that the regulation of NOX2/ROS by Hv-1 contributes to NP [198]. Moreover, the benefits of Hv1 in reducing inflammatory pain and morphine-induced hyperalgesia and tolerance were also confirmed by pharmacological blockade of Hv1 or knockdown of the HV1 gene [199]. Interestingly, studies have confirmed that Hv1 promotes cancer cell growth and metastasis [200]. Based on these results, it is a good candidate target for relieving pain, especially cancer pain.

The transient receptor potential ankyrin 1 (TRPA1) channel, a nonselective cation channel expressed in the terminals of sensory nerves, is susceptible to modulation by ROS [201]. Significantly, Logu et al. demonstrated that allyl isothiocyanate, a TRPA1 agonist, was found to stimulate the release of ROS from HEK293 cells [156]. This suggests that TRPA1 not only responds to ROS as a downstream target but may also contribute to the generation of ROS or modulation of ROS levels. Following pSNI, NOX2-dependent oxidative bursts in infiltrating macrophages around damaged nerves activate the TRPA1/NOX1/ROS pathway in Schwann cells, subsequently maintaining their recruitment to macrophages and targeting TRPA1 on adjacent nociceptors to improve their efficacy [156]. This regulatory mechanism is also involved in the maintenance of chronic ethanol intake-induced mechanical pain and nitroglycerin-induced trigeminal neuralgia [202, 203]. These data indicate the existence of a cycle that perpetuates an oxidative stress status and involves the mutual induction of ROS generation and TRPA1 expression. Therefore, focusing on controlling or inhibiting these two factors seems to be a highly intriguing therapeutic strategy. Indeed, disruption of the indirect autostimulation circuit by TRPA1 knockout or pharmacological inhibition significantly reduces ROS production in the sciatic nerves of CCI rats, thereby exerting a potent analgesic effect [204].

ATP acts through the ligand-gated ion channel receptor purinergic type 2X (P2X) and metabolism-related G protein-coupled receptor purinergic type 2Y (P2Y) signaling pathways. The activation of these receptors induces the generation of ROS and alters antioxidant defenses, regulating the redox biology of cells [205]. A previous experiment that used P2X7R knockout mice revealed that P2X7R has a partial pronociceptive effect in CFA-induced inflammation and SNI-induced NP [206]. This facilitating role of P2X7R in nociception was further confirmed by a study showing that intrathecal administration of the P2X7R agonist BzATP markedly induces ROS expression and spontaneous nociceptive behavior. More importantly, PBN alleviates BzATP-induced pain behavior without rescuing P2X7R activation. All these results suggest that P2X7R is upstream of ROS dysregulation and is the critical mediator of pathogenic inducement [207]. This is consistent with the in vitro findings of Apolloni et al., who showed that P2X7R stimulates the translocation of p67phox and recruitment of Rac1 to induce NOX2-derived ROS production [208]. In cultured neuronal SH-SY5Y cells, pharmacological inhibition or knockdown of P2Y6R prevents increases in ROS and malondialdehyde levels and the downregulation of superoxide dismutase 1 expression following 1-methyl-4-phenylpyridinium stimulation [209]. Based on these data, P2Y6R may be implicated in chronic pain. Unsurprisingly, the P2Y6R antagonist MRS2578 was found to play a key role in attenuating pain behavior in CCI rats due to its ability to inhibit oxidative stress [210]. Moreover, Cirillo et al. demonstrated that administration of OxATP reversed SNI-induced glial activation, reduced expression of vesicular GABA transporter and glutamate transporter 1, and increased expression of vesicular glutamate transporter 1, thereby preventing neuropathic behavior [211]. These findings provide valuable insights into the role of ATP in chronic pain.

Toll-like receptor-4 (TLR4) acts as a pathogen-associated molecular pattern receptor. In vitro studies conducted by Park et al. using a luciferase assay revealed that the Toll-IL-1R domain of TLR4 binds to the COOH-terminal region of NOX4 and regulates its expression [212]. Heme is supposed to be an endogenous agonist of TLR4 [213]. This was confirmed in vitro in sickle microglial cells where heme increased endogenous ROS levels. This increase in ROS level was abolished by TAK242 or LPS-RS (a TLR4 inhibitor) [214]. Lei et al. showed that in sickle mice, TLR4 transcript levels were significantly increased in the spinal cord, and this alteration was responsible for chronic sickle pain. Specifically, TLR4 knockout or TLR4 inhibitors achieve similar effects in reducing mechanical, heat, and cold sensitivity in sickle mice [214]. Additionally, there is a negative correlation between TLR4 expression and the apoptotic index of neural cells in the prefrontal cortex region exposed to hyperoxia [25]. It should be noted that TLR4 plays an integral role in the body's immune defense. Therefore, periodic pathogen surveillance/clearance is necessary for long-term TLR4 inhibition to prevent unintended consequences related to the duration/extent of infection [215].

Sigma-1 (Sig-1) receptors are widely distributed in the CNS, and their activation enhances intracellular Ca2+ signaling by both mobilizing Ca2+ release from endoplasmic stores and prompting Ca2+ entry through the plasma membrane [216], thus resulting in increased activation of PKC [217], which leads to NOX2 activation by boosting the plasma membrane translocation of p47phox [218]. Indeed, intrathecal injection of PRE084 (a Sig-1R agonist) increases the activation of NOX2 and phosphorylation of NMDA receptor GluN1 subunit (pGluN1) at the Ser896 site in the dorsal horn [219, 220]. Importantly, this practice induces a rapid pronociceptive effect, which can be prevented by pretreatment by intrathecal injection with apocynin (a NOX inhibitor), confirming that NOX is a critical downstream target of Sig-1R-induced nociceptive hypersensitivity in mice. The positive regulation of Sig-1R-induced NOX2 signaling in the spinal cord is also a latent mechanism of injury in NP. Intrathecal injection of BD1047 (a Sig-1R antagonist) inhibits the supposedly boosted spinal NOX2 activation and ROS generation induced by CCI, reducing mechanical pain hypersensitivity. Furthermore, this regulation may partly occur at the posttranslational level, as a single administration of PRE084 to activate Sig-1R did not increase the expression of total p47phox but only the membrane fraction [219]. In addition, the optimal window for the analgesic effects of Sig-1R antagonism is in the induction phase of chronic NP, not the maintenance phase. Based on these findings, preemptive or reactive analgesia to modulate the establishment of chronic pain states and alter the course of NP would be of considerable clinical value in patients who experience direct nerve injury or those with cancer who are treated with chemotherapeutic agents [221].

Interleukin-33 (IL-33) is a nuclear factor derived from the IL1 family that exerts its biological functions by binding to the receptor complex composed of suppression of tumorigenicity 2 (ST2) receptor [222]. As shown in recent studies, it binds to ST2 in peripheral sensory neurons under pain conditions, induces the hyperexcitability of sensory neurons, and mediates nociception [222]. Recent experimental results have confirmed a critical role for IL-33/ST2 in the bidirectional regulation of ROS under pain conditions. ST2 knockout in mice or pharmacological inhibition of ST2 abolishes ROS overexpression and pain hypersensitivity in gout arthritis models, all of which are reversed by exogenous IL-33 [223].

Sphingosine-1-phosphate receptor 2 (S1P2) is a G protein-coupled receptor for sphingosine 1-phosphate (S1P), and its expression in the spinal cord is reduced in mice with CCI-induced NP. This modulation is associated with NP, as intrathecal injection with adeno-associated virus‐S1P2 suppresses ROS generation and reverses established pain [224]. Of note, the analgesic effect of S1P2 appears to be receptor independent, as the hypothesized downregulation of mechanical sensitivity in rats do not occur after SIP1 administration [224]. In addition, the expression of runt-related transcription factor 3, a critical protein involved in the growth and survival of DRG neurons [225], is also regulated in both directions by S1P2, with S1P2 knockdown or overexpression down- or upregulating runt-related transcription factor 3 levels, respectively [224].

Numerous studies have shown that the adverse effects of endothelin signaling in chronic pain are dependent on superoxide anion production, and endothelin receptor antagonists inhibit oxidative stress and reverse KO2-induced painful behaviors [226, 227].

MicroRNAs (miRNAs) are involved in a variety of physiological and pathological processes and play important roles in the epigenetic regulation of gene expression, in addition to exerting effects at the transcriptional and posttranscriptional levels [228]. First, YB Im et al. confirmed a causal role for NOX4 in NP. Next, they investigated the importance of microRNA23b (miR23b) in NP, as it directly represses the translation of its target gene NOX4 by binding to complementary target mRNAs to elucidate the underlying upstream regulatory mechanism. The level of miR23b in the spinal cords of female mice with SCI-induced NP was significantly lower than that in wild-type animals. After an intrathecal injection of miR23b, the mechanical pain threshold was significantly increased [229]. Moreover, in a rescue experiment, NOX4 knockout occluded the anti-miR23b analgesic effect, confirming the involvement of miR23b mediated NOX4 regulation in NP [229]. Miao et al. also proposed that NOX4 may be a miR155 target in the context of pain. In oxaliplatin-induced NP, they quantified the expression of NOX4 and found that it was significantly upregulated in the SDH after oxaliplatin treatment. They analyzed miR155 expression in the same animals and observed a steady increase in miR155 expression, suggesting a causal relationship between miR155 and NOX4. Intrathecal injection of a miR155 inhibitor reduced NOX4 expression in the SDH and significantly alleviated pain behaviors in rats [18]. Similarly, SCI induced a fast and steady increase in miR-155 expression in the early postoperative period, and these phenomena disappeared in the absence of NOX2 [155]. These results suggest that miR-155 may present an integrative role between NOX2 and NOX4 events in ROS-induced NP, and we can regulate the expression of multiple genes through one miRNA or finely regulate the expression of a certain gene through a combination of several miRNAs, thereby affecting a wide range of targets in the pain pathways [230]. Because of the conserved of miRNA properties across animal species and their sequence specificity, as well as the easy delivery of peptide nucleic acids used to suppress miRNAs, miRNAs have inherent advantages for drug targeting [231].

4 TARGETING PEROXISOME FOR CHRONIC PAIN THERAPY

Various FAD-dependent oxidoreductases in peroxisomes are the main sources of cellular generation of H2O2 [232]. Peroxisomes are equipped with enzymatic and nonenzymatic antioxidant systems to maintain their own redox balance [233]. D-amino acid oxidase (DAAO), the earliest enzyme detected in peroxisomes [234], is widely present in pain perception areas of both the brain and spinal cord [235, 236]. It catalyzes the oxidative deamination of d-amino acids in the following manner to generate the catalytic cycle byproduct H2O2 in vitro and in vivo: R-CH(NH2)-COOH + O2 + H2O → R – CO2 - COOH + NH3+ H2O2 [234]. It plays an important role in chronic pain transmission and transduction due to augmented production of H2O2, including in formalin-induced tonic pain, bone cancer pain, SNI-induced mechanical allodynia and sleep-deprived mechanical hypersensitivity as well as morphine tolerance. Evidence for this phenomenon includes the fact that the levels of DAAO and ROS are increased in the pain models described above and that genetic ablation or pharmacologic blockade of DAAO attenuates pain behaviors [235, 237-243]. Interestingly, in CCI and trigeminal neuropathic rats, exogenous DAAO exerts an antinociceptive effect [244-246]. A plausible explanation for this finding is that D-serine is an endogenous agonist of NMDA, which is involved in central sensitization, and the D-serine level decreases as a result of the degradation of D-serine by DAAO [247]. Unfortunately, the recent evidence does not fully explain the dual roles of DAAO in the occurrence and development of chronic pain.

CONCLUDING REMARKS AND FUTURE PERSPECTIVES

Recent studies have challenged the traditional approach of controlling pain through ROS scavenging. Instead, researchers are now focusing on controlling the sources of ROS. While inhibiting NOX has been a primary focus, its control should extend beyond direct inhibition. Novel treatments regulate NOX by preventing abnormal activation via the assembly of each subunit or targeting the upstream mechanism involved in the signaling pathway. Additionally, maintaining normal electron transport in the MRC and modulating mitochondrial mass regulation have been shown to be promising therapeutic strategies for chronic pain. This article reviews preclinical evidence from these types of studies to provide a broader perspective on the treatment of chronic pain (Table 1). However, these findings also raise further questions. First, considering that researchers have mainly focused on reducing ROS levels to relieve pain, the specific mechanisms through which these processes activate the MRC or NOX need to be further examined. Second, due to the complex nature of oxidative stress responses, relying solely on targeted molecular interventions may be too simple of an approach. A deeper understanding of the redox biology involved in chronic pain is essential for effectively managing it through antioxidant therapy. Third, while most studies rely on rodent models, the differences between animal species present significant challenges. To overcome these challenges, transgenic animals that express human receptors can be used to minimize these differences. Fourth, although the generation and regulation of ROS have been discussed individually, it is challenging to determine which specific part of the ROS generation process produce the effect. How ROS in different subcellular compartments communicate and affect cellular functions requires further exploration. Fifth, inhibiting certain molecules with various physiological functions may result in wide-ranging molecular and cellular consequences. Further evaluation is needed to determine whether they can serve as potential therapeutic targets after intervention. Sixth, despite the crucial role of certain pathways or molecules, such as diacylglycerol/PKC, in regulating ROS [248], there is a noticeable lack of specific studies investigating the diacylglycerol/PKC-NADPH oxidase pathway in pain management. It is crucial for future research to extensively explore this pathway, aiming to unravel its potential contributions and underlying mechanisms, which will provide valuable insights into the involvement of ROS in pain processes and open up new avenues for the development of pain management strategies. Encouragingly, the discovery of new pain-relieving effects in existing drugs brings great potential for drug repurposing [249]. By optimizing these drugs as a skeletal structure, the time needed for early-stage compound discovery and optimization can be significantly reduced. Moreover, with clear pharmacokinetic properties and safety parameters, the risk of failure in clinical trials can be effectively minimized.

Although we have discussed the targets involved in regulating ROS for pain management separately, it is undeniable that there are associations among some of these targets. For instance, there exists a complex interplay between ATP, P2X7 receptors, and AMPK, enabling the modulation of multiple signaling pathways with a common target ROS [250]. As such, multi-level regulation including ROS can be achieved by modulating any of the components within ATP, P2X7 receptors, or AMPK.

Overall, ROS have also been reported to exert beneficial effects, and both the differentiation and polarization of CNS neurons depend on a certain level of ROS [184]. Physiological ROS concentrations in specific subcellular sites play important regulatory roles in maintaining cellular homeostasis through protein phosphorylation, transcription factor regulation and signaling functions. Mastering the activation pattern of ROS by monitoring the generation of specific ROS in specific subcellular components and under specific conditions and then administering antioxidant treatment to specific microregions in cells will be beneficial for our management of ROS in the precise treatment of chronic pain. In addition, the specificity of NADPH-derived ROS-mediated signal transduction is related to the localization of NOX isoforms and regulatory subunits in specific subcellular compartments [251]. Whether ROS activated by different signaling pathways have different signatures may be an interesting topic.

ACKNOWLEDGEMENTS

I would like to express my thanks to the developers of the mapping software of biorender.

LIST OF ABBREVIATIONS

5-HT 5-hydroxytryptamine

AMPK Adenosine Monophosphate-activated Protein Kinase

APE1 Apurinic/Apyrimidinic Endonuclease 1

CA Carbonic Anhydrase

Cav-1 Caveolin-1

CCI Chronic Constriction Injury

CCL2 C-C motif Chemokine Ligand 2

CFA Complete Freund's Adjuvant

CNS Central Nervous System

CoQ Coenzyme Q

CREB cAMP-response Element-binding Protein

DAAO d-Amino Acid Oxidase

DRG Dorsal Root Ganglia

DRP1 Dynamic-associated Protein 1

ER Endoplasmic Reticulum

FAD Flavin Adenine Dinucleotide

FADH2 1,5-Dihydroflavin Adenine Dinucleotide

FIS1 Mitochondrial Adaptor Fission 1

GABA Gamma-aminobutyric

Hv1 Hydrogen Voltage-gated Channel 1

IL-33 Interleukin-33

MAO Monoamine Oxidase

mEPSCs Miniature Excitatory Postsynaptic Currents

miR155 MicroRNA155

miR23b MicroRNA23b

miRNAs MicroRNAs

MMP Mitochondrial Membrane Potential

MRC Mitochondrial Respiratory Chain

Mst1 Mammalian ste20-like kinase1

NADPH Nicotinamide Adenine Dinucleotide Phosphate

NF-κB Nuclear Factor-kappa B

NLRP3 NOD-like Receptor Thermal Protein Domain Associated Protein 3

NMDA N-methyl-D-aspartate

NP Neuropathic Pain

NRF1 Nuclear Respiratory Factor 1

NRF2 Nuclear Factor Erythroid 2-related Factor 2

OPA1 Optic Atrophy 1 Protein

P2X Purinergic Type 2X

P2Y Purinergic Type 2Y

PGC-1α Peroxisome Proliferator-activated Receptor-gamma Coactivator-1alpha

PKC Protein Kinase C

pSNL Partial Sciatic Nerve Ligation

Ref-1 Redox Factor-1

RNS Reactive Nitrogen Species

ROS Reactive Oxygen Species

RyR Ryanodine Receptor

S1P Sphingosine 1-phosphate

S1P2 Sphingosine-1-phosphate Receptor 2

SCI Spinal Cord Injury

SDH Spinal Dorsal Horn

sEPSCs Spontaneous Excitatory Postsynaptic Currents

Sig-1 Sigma-1

sIPSCs Spontaneous Inhibitory Postsynaptic Currents

siRNA Small Interfering RNA

SIRT Sirtuins

SNI Spared Nerve Injury

SNL Sciatic Nerve Ligation

ST2 Suppression of Tumorigenicity 2 Receptor

STZ Streptozotocin

TFAM Mitochondrial Transcription Factor A

TLR4 Toll-like-receptor-4

TNFα Tumor Necrosis Factor α

TRPA1 Transient Receptor Potential Ankyrin 1

UCP Uncoupling Protein

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

This study was funded by Shanxi Province “136 Revitalization Medical Project Construction Funds”, National Natural Science Foundation of P.R. China 81873732 and Shanxi Provincial Health Commission Funds in Shanxi Bethune Hospital No. 2020009 to Da-Wei Ye.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

Fig. (1) The role of mitochondrial respiratory chain and quality control system in ROS generation. The normal transfer (blue arrows) and leakage process (dotted arrows) of electrons in the mitochondrial respiratory chain. Complex I allows electrons from NADH to enter the mitochondrial respiratory chain [49], Complex II transfers electrons from succinate to CoQ, Complex III transports electrons to cytochrome c and creates a proton gradient [50], Complex IV combines electrons from cytochrome c with oxygen to form water [51], and Complex V synthesizes ATP using the proton gradient [52]. UCP decrease electron leakage and reduce ROS by enhancing normal proton and electron transport. The quality control system of mitochondria maintains their structure and function. If damaged, it disrupts electron flow in the inner membrane, causing more leaked electrons to react with oxygen and generate excessive ROS. (This figure was created with BioRender.com). Abbreviations: I: complex I; II: complex II; III: complex III; IV: complex IV; CoQ: coenzyme Q; CytC: cytochrome C; NADH: nicotinamide adenine dinucleotide; FADH2: 1,5-dihydroflavin adenine dinucleotide; FAD: flavin adenine dinucleotide; UCP: uncoupling protein; DRP1: dynamic-associated protein 1; MFF: mitochondrial fission factor; FIS1: mitochondrial adaptor fission 1; MiD49: mitochondrial dynamics proteins of 49 kDa; MiD51: mitochondrial dynamics proteins of 51 kDa; OPA1: optic atrophy 1 protein; MFN1: mitofusins1; MFN2: mitofusins2; PGC-1α: peroxisome proliferator-activated receptor-gamma coactivator-1alpha; NRF1: nuclear respiratory factor 1; NRF2: nuclear factor erythroid 2-related factor 2; TFAM: mitochondrial transcription factor A.

Fig. (2) The role of NADPH oxidase family in ROS generation. Rac1 is activated when it binds to GTP and is inactivated when it binds to GDP. Guanine nucleotide exchange factor (GEF) is responsible for the conversion of GDP to GTP, and GTP-activating proteins (GAPs) promote Rac1 proteolysis. Guanine nucleotide dissociation inhibitors (GDIs) block the activation pathway of Rac1 [173, 174]. p67phox, p40phox and activated Rac1 are assembled and then induced to bind and translocate to the cell membrane by phosphorylated p47phox, where they combine with the complex composed of p22phox and gp91phox in the plasma membrane to form the active form of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. The NOX protein contains binding sites for NADPH, flavin adenine dinucleotide (FAD) and heme. The NADPH substrate donates two electrons, and these electrons are transferred to FAD, which is reduced to FADH2. FADH2 transfers the first electron to the cytochrome proximal ferrous to form the semiquinone-based form of FAD, which is rapidly transferred to the distal heme to form ROS with the molecular oxygen acceptor. The second electron carried by the semiquinone-based FAD combines with oxygen molecules in the same way to form ROS [146]. (This figure was created with BioRender.com).

Table 1 Summary of therapeutic potential of following targets or pathways in chronic pain.

-	Target	Drug	Model	Treatment Strategy	Effects	Mechanisms	References	
Mitochondria-related analgesic targets	Complex I	Rotenone (complex I inhibitor)	VCR, ddC, and STZ-induced neuropathic
pain rats	Rotenone (1, 2, 5 and 10 μg, i.d.) was administered from day 5 to 8 after VCR, ddC, and STZ injection.	PWT↑	Restore MRC dysfunction	[56]	
TNFα-induced inflammatory pain rats	Rotenone (1, 2, 5 and 10 μg, i.d.) was co-injected with TNFα.	PWT↑	Restore MRC dysfunction	[56]	
Paclitaxel-induced neuropathic pain rats	Rotenone (3 mg/kg, i.p.) was administered after paclitaxel injection.	PWT↓	MRC dysfunction	[59]	
Oxaliplatin-induced neuropathic pain rats	Rotenone (3 mg/kg, i.p.) was administered after oxaliplatin injection.	PWT↓	MRC dysfunction	[59]	
Complex II	3-Acetylphenyl
N-(P-Tolyl) carbamate (complex II inhibitor)	VCR, ddC, and STZ-induced neuropathic pain rats	3-Acetylphenyl N-(P-Tolyl) carbamate (1, 2, 5 and 10 μg, i.d.) was administered from day 5 to 8 after VCR, ddC, and STZ injection.	PWT↑	Restore MRC dysfunction	[56]	
TNFα-induced inflammatory pain rats	3-Acetylphenyl N-(P-Tolyl) carbamate (1, 2, 5 and 10 μg, i.d.) was co-injected with TNFα.	PWT↑	Restore MRC dysfunction	[56]	
Complex III	Antimycin A (complex III
inhibitor)	VCR, ddC, and STZ-induced neuropathic pain rats	Antimycin A (1, 2, 5 and 10 μg, i.d.) was administered from day 5 to 8 after VCR, ddC, and STZ injection.	PWT↑	Restore MRC dysfunction	[56]	
Paclitaxel-induced neuropathic pain mice	Antimycin A (0.2 and 0.4 mg/kg, i.p.) was administered once daily for 7 days before and during paclitaxel treatment on days -1 to 5.	PWT↑	Restore MRC dysfunction	[58]	
TNFα-induced inflammatory pain rats	Antimycin A (1, 2, 5 and 10 μg, i.d) was co-injected with TNFα.	PWT↑	Restore MRC dysfunction	[56]	
Complex IV	Sodium cyanide (complex IV
inhibitor)	VCR, ddC, and STZ-induced neuropathic pain rats	Sodium cyanide (1, 2, 5 and 10 μg, i.d.) was administered from day 5 to 8 after VCR, ddC, and STZ injection.	PWT↑	Restore MRC dysfunction	[56]	
TNFα-induced inflammatory pain rats	Sodium cyanide (1, 2, 5 and 10 μg, i.d) was
co-injected with TNFα.	PWT↑	Restore MRC dysfunction	[56]	
Complex V	Oligomycin
(complex V
inhibitor)	VCR, ddC, and STZ-induced neuropathic pain rats	Oligomycin (1, 2, 5 and 10 μg, i.d.) was administered from day 5 to 8 after VCR, ddC, and STZ injection.	PWT↑	Restore MRC dysfunction	[56]	
TNFα-induced inflammatory pain rats	Oligomycin (1, 2, 5 and 10 μg, i.d) was co-injected with TNFα.	PWT↑	Restore MRC dysfunction	[56]	
Paclitaxel-induced neuropathic pain rats	Oligomycin (10 mg/kg, i.p.) was administered after oxaliplatin injection.	PWT↓	MRC dysfunction	[59]	
Oxaliplatin-induced neuropathic pain rats	Oligomycin (10 mg/kg, i.p.) was administered after oxaliplatin injection.	PWT↓	MRC dysfunction	[59]	
CoQ	Idebenone
(CoQ10 analog)	Carrageenan-induced inflammatory pain rats	Idebenone (1, 5 and 10 mg/kg, i.p.) was administered 15 minutes before the administration of the stimulus.	PWL↑	ROS↓ MnSOD nitration↓	[67]	
CA	5b
(CAVA inhibitor)	Paclitaxel-induced neuropathic pain mice	5b (100 mg/kg, p.o.) was administered on day 10 or from day 1 to 15 after paclitaxel injection.	PWL↑	MMP↓ Microglia activation↓ Astrocyte activation↓	[75]	
5d
(CAVB inhibitor)	Paclitaxel-induced neuropathic pain mice	5d (100 mg/kg, p.o.) was administered on day 10 or from day 1 to 15 after paclitaxel injection.	PWL↑	MMP↓ Microglia activation↓ Astrocyte activation↓	[75]	
FAM173B	AS-mFAM173B	CFA-induced inflammatory pain mice	AS-mFAM173B was administered from day 5 to 10 after the CFA injection.	PWL↓ PWT↓	MMP↑ ROS↑ Microglia
activation↑	[77]	
SNI-induced neuropathic pain mice	AS-mFAM173B was administered from day 1 to 9 after the SNI injury.	PWL↓ PWT↓	MMP↑ ROS↑ Microglia
activation↑	[77]	
DRP1	AS-DRP1	Remifentanil-induced hyperalgesia rats	AS-DRP1 (10 μg, i.t.) was administered 30 minutes before remifentanil infusion.	PWT↑ PWL↑	DRP1↓ ROS↓ NMDA↓	[88]	
Mdivi-1
(DRP1 inhibitor)	HIVgp120-induced neuropathic pain rats	Mdivi-1 (3 μl, i.t.) was administered from day 1 to 3 after gp-120 treatment.	PWT↑	DRP1↓ ROS↓	[90]	
2-Bromopalmitate (palmitoylation inhibitor)	CFA-induced inflammatory pain rats	2- Bromopalmitate (0.1 and 0.5 mg/kg, i.t.) was administered one day before the CFA injection.	PWT↑	DRP1↓ OPA1↑ ROS↓
IL-1β↓ TNFα↓ Astrocyte activation↓	[93]	
Mitochondria-related analgesic targets	DRP1	Mito -TEMPO	CCI-induced neuropathic pain rats	Mito-TEMPO (0.7 mg/kg, i.p.) was administered from day 7 to 21 after CCI injury.	PWT↑ PWL↑	DRP1↓ FIS1↓ OPA1↑ MFN1↑ ROS↓	[91]	
PGC-1α	Recombinant
PGC-1α	Morphine-induced morphine-tolerant rats	Recombinant PGC-1α (20 ng, i.t.) was administered 30 minutes before morphine injection.	PWT↑ PWL↑	PGC-1α↑ ROS↓	[17]	
ZLN005
(PGC-1α activator)	SNI-induced neuropathic pain rats	ZLN005 (50 μg, i.t.) was administered after SNI injury for 7 days.	PWT↑	PGC-1α↑ ROS↓	[100]	
NRF2	RTA-408
(NRF2 activator)	CCI-induced neuropathic pain mice	RTA-408 (1, 5 and 10 μg, i.t.) was administered from day 7 to 11 after CCI injury.	PWT↑ PWL↑	PGC-1α↑ ROS↓	[98]	
MAO	KDS2010
(MAO-B inhibitor)	Paclitaxel-induced neuropathic pain mice	KDS2010 (15, 25 and 50 mg/kg, p.o.) was administered twice daily after paclitaxel injection for 14 days.	PWT↑	ROS↓ Astrocyte activation↓
Restores sIPSCs	[105]	
5-HT(1F)	Lasmiditan
(5-HT(1F) receptor agonist)	SNI-induced neuropathic pain rats	Lasmiditan (100 and 200 μg, i.t.) was administered after SNI injury for 12 days.	PWT↑	PGC-1α↑ ROS↓	[100]	
ADRB2	Formoterol fumarate dihydrate (ADRB2 agonist)	Paclitaxel-induced neuropathic pain rats	Formoterol (5, 25 and 50 μg, i.t.) was administered on the 14th day after the first injection of paclitaxel.	PWT↑	PGC-1α↑ NRF1↑ TFAM↑ ROS↓	[99]	
P53	Pifithrin-α
(P53 selective inhibitor)	STZ-induced diabetic neuropathic pain mice	Pifithrin-α (1.1 mg/kg, i.p.) was administered three times weekly for 4 weeks starting on the first day of STZ treatment.	PWT↑ PWL↑	P53↓ Parkin↑ ROS↓	[115]	
Pifithrin-µ
(P53 selective inhibitor)	Paclitaxel-and cisplatin-induced neuropathic pain rats	Pifithrin-µ (8 mg/kg, i.p.) was administered 1 hour before paclitaxel or cisplatin injection.	PWT↑	P53↓ MMP↑ ROS↓	[116,117]	
Mst1	Mst1 siRNA	CCI-induced neuropathic pain rats	A 120 μl mixture of gel and siRNA was dripped surrounding the sciatic nerve immediately after the ligation.	PWT↑ PWL↑	MMP↑ ROS↓ p62↓ Parkin↓	[120]	
SIRT1	Ro5-4864
(TSPO agonist)	SNI-induced neuropathic pain rats	Ro5-4864 (2 μg, i.t.) was administered from day 3 to 5 after surgery.	PWT↑	SIRT1↑ PGC-1α↑ Beclin1↓ LC3↓ P62↓	[125]	
SIRT3	LV-SIRT3	STZ-induced diabetic neuropathic pain rats	LV-SIRT3 (10 μl/day, i.t.) was administered for 5 days after 15 days of STZ injection.	PWT↑ PWL↑	FOXOa3↑ MnSOD↑ Catalase↑	[129]	
SNI-induced neuropathic pain rats	LV-SIRT3 (5 μl/day, i.t.) was administered for 5 days after 15 days of STZ injection.	PWT↑ PWL↑	Ac-CypD↓ mPTP↓ MMP↑ ROS↓	[19]	
AMPK	AICAR
(AMPK activator)	Cancer-induced bone pain rats	AICAR (1 mg/kg, i.t.) was administered after the CIBP animal model was established.	PWT↑	AMPK↑ ROS↓ DRP1↓ IL-1β↓ NLRP3↓	[141]	
Metformin
(AMPK activator)	Non-obese type 2 diabetic mice	Metformin (150 mg/kg, i.p.) was administered
after SNI injury for 13 weeks.	PWT↑ PWL↑	AMPK↑ NOX↓ Beclin-1↓ LC3↓ ROS↓	[143]	
NOX-related analgesic targets	Rac1	NSC23766
(Rac1 inhibitor)	Burn injury-induced neuropathic pain mice	NSC23766 (5 μg, i.t.) was administered twice daily for 3 days after burn injury.	PWT↑ PWL↑	Rac1↓ Dendritic spine density↓	[176]	
Paclitaxel-induced neuropathic pain rats	NSC23766 (10 μg, i.t.) was administered on days 15, 20 and 25 after paclitaxel treatment.	PWT↑	Rac1↓ Dendritic spines maturity↓	[177]	
APE1/Ref-1	E3330 (selective inhibitor of APE1-redox activity)	CFA-induced inflammatory pain rats	E3330 (10 μl, i.t.) was administered 5 minutes before CFA injection.	PWT↑	APE1↑ Rac1↓ ROS↓ NF-κB↓
IL-6↓	[180]	
RyR	Dantrolene (antagonist of RyR)	HIVgp120-induced neuropathic pain rats	Dantrolene (1, 3 and 10 µm, i.t.) was administered 2 weeks after HIV gp120 injection.	PWT↑	ROS↓	[186]	
Cav-1	Daidzein (Cav-1 specific inhibitor)	STZ-induced diabetic neuropathic pain mice	Daidzein (0.4 mg/kg/day, i.p.) was administered for 2 weeks after 14 days of STZ injection.	PWT↑ PWL↑	Cav-1↑ Rac1↓ NOX2↓ ROS↓ NR2B↓	[189]	
p47phox	Curcumin	STZ-induced diabetic neuropathic pain mice	Curcumin (200 mg/kg, i.e.) was administered for 14 days after STZ injection.	PWT↑	p47phox↓ gp91phox↓ ROS↓ MDA↓ SOD↑	[191]	
Hv1	YHV98-4
(Hv1 specific inhibitor)	CFA-induced inflammatory pain mice	YHV98-4 (10 mg/kg, i.p.) was administrated twice daily for 2 days after CFA injection.	PWT↑ PWL↑	Hv1 ↓ ROS↓
SHP-1↑	[199]	
Opioid-induced tolerance and hyperalgesia in mice	YHV98-4 (10 mg/kg, i.p.) was administrated for 6 days after the first injection of CFA.	PWT↑ PWL↑	Hv1↓ Restore
ROS-SHP-1-PI3K/ pAKT-CXCL1 pathway	[199]	
NOX-related analgesic targets	TRPA1	HC030031 or A967079
(TRPA1 selective antagonist)	pSNL-induced neuropathic pain mice	HC030031 (100 mg/kg, i.p.) or A-967079 (100 mg/kg, i.p.) was administered on day 10 after surgery.	PWT↑
PWL→	TRPA1↓ NOX1↓ ROS↓	[156]	
Glyceryl trinitrin-induced migraine in mice	HC030031 (100 mg/kg, i.p.) or A-967079 (100 mg/kg, i.p.) was administered 0.5 hour before and 1, 3, 4 and 5 hours after glyceryl trinitrin injection.	PT↑	TRPA1↓ NOX1↓ ROS↓	[203]	
A967079
(TRPA1 selective antagonist)	Ethanol-induced neuropathic pain mice	A967079 (100 mg/kg, i.p.) was administered on day 28 after ethanol.	PWT↑	TRPA1↓ NOX1↓ ROS↓	[202]	
P2	OxATP
(nonselective P2XR antagonist)	SNI-induced neuropathic pain mice	OxATP (6 mg/kg, i.p.) was administered from day 1 to 21 after surgery.	PWT↑ PWL↑	Microglial activation↓ Astrocytic activation↓ GLT1↓ vGAT↓ vGLUT1↑ P2X7R↓ ROS↓	[211]	
A438079
(P2X7R antagonist)	BzATP-induced nociceptive pain mice	A438079 (100 mg/kg, i.p.) was administered 30 minutes before the injection of BzATP.	PLR↑	P2X7R↓ ROS↓	[207]	
MRS2578
(P2Y6R antagonist)	CCI-induced neuropathic pain rats	MRS2578 (10 μl, i.t.) was administered on days 3, 7 and 14 after surgery.	PWT↑ PWL↑	P2Y6R↓ ROS↓ SOD↑ GSH↑
HO-1↑	[210]	
TLR4	TAK242
(TLR4 inhibitor)	Heme-induced chronic pain in sickle mice	TAK242 (1 mg/kg/day, i.v.) was administered for 5 days after model establishment.	PWT↑ PWL↑	TLR4↓ ROS↓
IL-6↓ Microglial activation↓	[214]	
Sig-1	BD1047
(Sig-1R antagonist)	CCI-induced neuropathic pain rats	BD1047 (100 nmol, i.t.) was administered twice daily on days 0–5 or 15–20 after surgery.	PWT↑ PWL→	Sig-1↓ NOX2↓ ROS↓	[219]	
S1P	S1P2 shRNA	CCI-induced neuropathic pain rats	S1P2 shRNA (2×1011 vector genomes per, i.t.) was administered 3 days before CCI surgery.	PWT↓ PWL↓	S1P2↓ ROS↑
IL-1β↓
IL-6↓ CCL2↓ RUNX3↓	[224]	
IL-33/ST2	IL-33 neutralizing antibody	MSU-induced gouty arthritis in mice	IL-33 neutralizing antibody (5 μg, i.p.) was administered 1 hour before and 8, 23 hours after model establishment.	PWT↑	IL-33↓ ROS↓ MDA↓
4-HNE↓ CXCL1↓ CCL3↓ IL-1β↓
IL-6↓	[223]	
ST2 neutralizing antibody	MSU-induced gouty arthritis in mice	ST2 neutralizing antibody (50 μg, i.p.) and IL-33 neutralizing antibody (300 ng, i.p.) were co-administered 24 hours after model establishment.	PWT↑	ST2↓ ROS↓ MDA↓
4-HNE↓ CXCL1↓ CCL3↓ IL-1β↓
IL-6↓	[223]	
Endothelin A	Clazosentan
(endothelin A receptor antagonist)	KO2-induced inflammatory pain mice	Clazosentan (3, 10 and 30 nmol, i.p.) was administered 30 minutes before KO2 injection.	PWT↑
PWL↑	ROS↓ IL-1β↓ TNFα↓ MPO↓	[227]	
Endothelin B	BQ-788
(endothelin B receptor antagonist)	KO2-induced inflammatory pain mice	BQ-788 (3, 10 and 30 nmol, i.p.) was administered 30 minutes before KO2 injection.	PWT↑
PWL↑	ROS↓ MPO↓	[227]	
miR23b	-	SCI-induced neuropathic pain rats	miR23b (10 μM, i.t.) was administered after surgery.	PWT↑ PWL↑	NOX4↓ ROS↓ COX2↓ TNFα↓
IL-1β↓ caspase-3↓ Bcl-2↑ GFAP↓ Iba1↓	[229]	
miR155	5′AAU UAC GAU UAG CAC UAU CCC CA-3′ (miR155 inhibitor)	Oxaliplatin-induced neuropathic pain rats	5′AAU UAC GAU UAG CAC UAU CCC CA-3′ (2 μg, i.t.) was administered for 5 days after oxaliplatin injection.	PWT↑ PWL↑	NOX4↓ NRF2↑ ROS↓ NQO1↑	[18]	
Peroxisome-related analgesic targets	DAAO	CBIO, sodium benzoate,
AS-057278 (DAAO selective inhibitors)	REMSD-induced pain rats	CBIO (3 μg, i.t.), sodium benzoate (30 and 100 μg, i.t.) and AS-057278 (3 and 10 μg, i.t.) were administered 48 hours after REMSD, respectively.	PWT↑	DAAO↓ ROS↓	[240]	
Morphine-induced analgesic tolerance rats and mice	CBIO (10 mg/kg, s.c.), AS057278 (40 mg/kg, s.c.) and sodium benzoate (400 mg/kg, s.c.) were administered for 7 days after the first injection of morphine, respectively.	PLR↑
TFL↑
PWL↑	DAAO↓ ROS↓	[241]	
CBIO (1, 3, and 10 mg/kg, s.c.), AS057278 (3, 10 and 30 mg/kg, s.c.) and sodium benzoate (10, 30, 100 and 300 mg/kg, s.c.) were administrated 20 minutes before morphine challenge.	PLR↑
TFL↑
PWL↑	DAAO↓ ROS↓	[241]	
Peroxisome-related analgesic targets	DAAO	Sodium Benzoate (DAAO selective inhibitor)	Acetic acid-induced visceral pain mice	Sodium benzoate (400 mg/kg, i.v.) was
administered 30 minutes before the administration
of the stimulus.	TFL↑
PLR↑	DAAO↓	[242]	
Formalin-induced inflammatory pain mice	Sodium benzoate (400 mg/kg, i.v.) was
administered 30 minutes before the administration
of the stimulus.	TFL↑
PLR↑	DAAO↓	[242]	
SUN
(DAAO inhibitor)	SNI-induced neuropathic pain rats	SUN (3, 10 and 30 mg/kg, p.o.) was administered from day 11 to 14 after surgery.	PWL↑	DAAO↓	[243]	
CCI-induced neuropathic pain rats	SUN (3, 10 and 30 mg/kg, p.o.) was administered from day 13 to 17 after surgery.	PWL↑	DAAO↓	[243]	
CFA-induced inflammatory pain rats	SUN (3, 10 and 30 mg/kg, p.o.) was administered after CFA injection.	PWL↑	DAAO↓	[243]	
Abbreviations: VCR: vincristine; ddC: 2’,3’-dideoxycytidine; STZ: streptozotocin; MRC: mitochondrial respiratory chain; CoQ: coenzyme Q; PWL: paw withdrawal latency; MnSOD: manganese superoxide dismutase; CA: carbonic anhydrase; AS-mFAM173B: antisense oligodeoxynucleotides against mFAM173B; CFA: complete Freund's adjuvant; PWT: paw withdrawal threshold; MMP: mitochondrial membrane potential; SNI: spared nerve injury; MONPs: manganese oxide nanoparticles; TFL: tail flick latency; COX2: cyclooxygenase 2; DRP1: dynamin-related protein 1; AS-DRP1: antisense oligodeoxynucleotides against DRP1; NMDA: N-methyl-D-aspartate; OPA1: optic atrophy 1; IL-1β: interleukin-1β; TNFα: tumor necrosis factor α; CCI: chronic constriction injury; FIS1: mitochondrial adaptor fission 1; MFN1: Mitofusins1; PGC-1α: peroxisome proliferator-activated receptor-gamma coactivator-1alpha; MAO: monoamine oxidase; 5-HT: 5-hydroxytryptamine; ADRB2: β2-adrenoreceptor; NRF1: nuclear respiratory factor 1; TFAM: mitochondrial transcription factor A; AMPK: adenosine monophosphate-activated protein kinase; CIBP: cancer-induced bone pain; NLRP3: NOD-like receptor thermal protein domain associated protein 3; FOXO: forkhead homeobox type O; NOX: nicotinamide adenine dinucleotide phosphate oxidase; Mst1: mammalian ste20-like kinase1; siRNA: small interfering RNA; SIRT1: sirtuin-1; TSPO: translocator protein; SNL: spinal nerve ligation; LC3: microtubule-associated protein 1 light chain 3; SIRT3: sirtuin-3; FOXOa3: forkhead homeobox type O 3a; Ac-CypD: cyclophilin D; mPTP: mitochondrial permeability transition pore; APE1: apurinic/apyrimidinic endonuclease 1; Ref-1: redox factor-1; NF-κB: nuclear factor kappa B; IL-6: interleukin 6; RyR: ryanodine receptor; Cav-1: caveolin-1; NR2B: NMDA receptor 2B; KO2: superoxide anion donor; NRF2: nuclear factor E2-related factor 2; HO-1: heme oxygenase-1; MDA: malondialdehyde; SOD: superoxide dismutase; LPS: lipopolysaccharide; TPPU: trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea; SEH: soluble epoxide hydrolase; ASC: apoptosis-associated speck-like protein containing a caspase activation and recruitment domain; NLRC4: nucleotide-binding and oligomerization domain-like receptor C4; iNOS: inducible nitric oxide synthase; nNOS:neuronal nitric oxide synthase; CCL2: C-C motif chemokine ligand 2; IL-33: interleukin-33; ST2: suppression of tumorigenicity 2 receptor; MSU: monosodium urate; 4-HNE: 4-hydroxynonenal; CXCL1: C-X-C motif chemokine ligand 1; CCL3: C-C motif chemokine ligand 3; S1P: sphingosine 1-phosphate; S1P2: sphingosine‐1‐phosphate receptor 2; RUNX3: runt‐related transcription factors 3; S1P1: sphingosine-1-phosphate receptor 1; Hv1: hydrogen voltage-gated channel 1; SHP-1: Src homology 2 domain-containing tyrosine phosphatase 1; PI3K: phosphatidylinositol-3 kinase; pAKT: phosphorylated protein kinase B; TRPA1: transient receptor potential ankyrin 1; P2: purinergic type 2; pSNL: partial sciatic nerve ligation; PT: periorbital threshold ; MPO: myeloperoxidase; sIPSCs: spontaneous inhibitory postsynaptic currents; miR23b: microRNA23b; SCI: spinal cord injury; GFAP: glia fibrillary acidic protein; miR155: microRNA155; NQO1: nicotinamide adenine dinucleotide phosphate quinone oxidoreductase-1; GLT1: glutamate transporter 1; vGAT: vesicular gamma-aminobutyric transporter; vGLUT1: vesicular glutamate transporter 1; P2X7R: P2X7 receptor; PLR: paw licking response; P2Y6R: P2Y6 receptor; GSH: glutathione; TLR4: toll-like receptor 4; Sig-1: sigma-1; Sig-1R: sigma-1 receptor; DAAO: d-amino acid oxidase; TFL: tail flick latency; REMSD: rapid eye movement sleep deprivation; SUN: 4H-furopyrrole-5-carboxylic acid; CBIO: 6-chlorobenzo[d]isoxazol-3-ol; i.d.: intradermally; i.g.: intragastrically; i.p.: intraperitoneally; i.t.: intrathecally; s.c.: subcutaneous; i.v.: intravenous; p.o.: oral; ↓: downregulated; ↑: upregulated; →: no effect.
==== Refs
REFERENCES

1 Mills S.E.E. Nicolson K.P. Smith B.H. Chronic pain: A review of its epidemiology and associated factors in population-based studies. Br. J. Anaesth. 2019 123 2 e273 e283 10.1016/j.bja.2019.03.023 31079836
2 Gaskin D.J. Richard P. The economic costs of pain in the United States. J. Pain 2012 13 8 715 724 10.1016/j.jpain.2012.03.009 22607834
3 Kela I. Kakarala C.L. Hassan M. Belavadi R. Gudigopuram S.V.R. Raguthu C.C. Gajjela H. Sange I. Chronic pain: A complex condition with a multi-tangential approach. Cureus 2021 13 11 e19850 10.7759/cureus.19850 34963858
4 Zhou Y.Q. Tian X.B. Tian Y.K. Mei W. Liu D.Q. Ye D.W. Wnt signaling: A prospective therapeutic target for chronic pain. Pharmacol. Ther. 2022 231 107984 10.1016/j.pharmthera.2021.107984 34480969
5 Chen S.P. Zhou Y.Q. Liu D.Q. Zhang W. Manyande A. Guan X.H. Tian Y. Ye D.W. Omar D.M. PI3K/Akt pathway: A potential therapeutic target for chronic pain. Curr. Pharm. Des. 2017 23 12 1860 1868 10.2174/1381612823666170210150147 28190392
6 Sørensen A.T. Rombach J. Gether U. Madsen K.L. The scaffold protein PICK1 as a target in chronic pain. Cells 2022 11 8 1255 10.3390/cells11081255 35455935
7 Vandenberg R.J. Ryan R.M. Carland J.E. Imlach W.L. Christie M.J. Glycine transport inhibitors for the treatment of pain. Trends Pharmacol. Sci. 2014 35 8 423 430 10.1016/j.tips.2014.05.006 24962068
8 Tian Y-K. Ye D-W. Ge M-M. Chen N. Zhou Y-Q. Yang H. Galectin-3 in microglia-mediated neuroinflammation: Implications for central nervous system diseases. Curr. Neuropharmacol. 2022 20 11 2066 2080 10.2174/1570159X20666220201094547 35105290
9 Zhou Y.Q. Liu D.Q. Chen S.P. Sun J. Zhou X.R. Luo F. Tian Y.K. Ye D.W. Cellular and molecular mechanisms of calcium/calmodulin-dependent protein kinase II in chronic pain. J. Pharmacol. Exp. Ther. 2017 363 2 176 183 10.1124/jpet.117.243048 28855373
10 Chhatwal J. Mueller P.P. Chen Q. Kulkarni N. Adee M. Zarkin G. LaRochelle M.R. Knudsen A.B. Barbosa C. Estimated reductions in opioid overdose deaths with sustainment of public health interventions in 4 US States. JAMA Netw. Open 2023 6 6 e2314925 10.1001/jamanetworkopen.2023.14925 37294571
11 Valko M. Leibfritz D. Moncol J. Cronin M.T.D. Mazur M. Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007 39 1 44 84 10.1016/j.biocel.2006.07.001 16978905
12 Veal E.A. Day A.M. Morgan B.A. Hydrogen peroxide sensing and signaling. Mol. Cell 2007 26 1 1 14 10.1016/j.molcel.2007.03.016 17434122
13 Lancaster J.R. Jr. Nitroxidative, nitrosative, and nitrative stress: Kinetic predictions of reactive nitrogen species chemistry under biological conditions. Chem. Res. Toxicol. 2006 19 9 1160 1174 10.1021/tx060061w 16978020
14 D’Autréaux B. Toledano M.B. ROS as signalling molecules: Mechanisms that generate specificity in ROS homeostasis. Nat. Rev. Mol. Cell Biol. 2007 8 10 813 824 10.1038/nrm2256 17848967
15 Shnayder N.A. Petrova M.M. Popova T.E. Davidova T.K. Bobrova O.P. Trefilova V.V. Goncharova P.S. Balberova O.V. Petrov K.V. Gavrilyuk O.A. Soloveva I.A. Medvedev G.V. Nasyrova R.F. Prospects for the personalized multimodal therapy approach to pain management via action on NO and NOS. Molecules 2021 26 9 2431 10.3390/molecules26092431 33921984
16 Xu B.Y. Sun J. Chen S.P. Wang X.M. Chen N. Li D.Y. Chen G. Mei W. Tian Y.K. Zhou Y.Q. Ye D.W. Nox2 contributes to reactive oxygen species-induced redox imbalance in cancer-induced bone pain. Am. J. Transl. Res. 2021 13 3 1269 1279 33841655
17 Kashiwagi Y. Yi H. Liu S. Takahashi K. Hayashi K. Ikegami D. Zhu X. Gu J. Hao S. Mitochondrial biogenesis factor PGC-1α suppresses spinal morphine tolerance by reducing mitochondrial superoxide. Exp. Neurol. 2021 339 113622 10.1016/j.expneurol.2021.113622 33516729
18 Miao F. Wang R. Cui G. Li X. Wang T. Li X. Engagement of MicroRNA-155 in exaggerated oxidative stress signal and TRPA1 in the dorsal horn of the spinal cord and neuropathic pain during chemotherapeutic oxaliplatin. Neurotox. Res. 2019 36 4 712 723 10.1007/s12640-019-00039-5 31016687
19 Yan B. Liu Q. Ding X. Lin Y. Jiao X. Wu Y. Miao H. Zhou C. SIRT3-mediated CypD-K166 deacetylation alleviates neuropathic pain by improving mitochondrial dysfunction and inhibiting oxidative stress. Oxid. Med. Cell. Longev. 2022 2022 1 17 10.1155/2022/4722647 36092157
20 Kallenborn-Gerhardt W. Schröder K. Del Turco D. Lu R. Kynast K. Kosowski J. Niederberger E. Shah A.M. Brandes R.P. Geisslinger G. Schmidtko A. NADPH oxidase-4 maintains neuropathic pain after peripheral nerve injury. J. Neurosci. 2012 32 30 10136 10145 10.1523/JNEUROSCI.6227-11.2012 22836249
21 Iqbal R. Mughal M.S. Arshad N. Arshad M. Pathophysiology and antioxidant status of patients with fibromyalgia. Rheumatol. Int. 2011 31 2 149 152 10.1007/s00296-010-1470-x 20376669
22 Xu J. Wei X. Gao F. Zhong X. Guo R. Ji Y. Zhou X. Chen J. Yao P. Liu X. Wei X. Nicotinamide adenine dinucleotide phosphate oxidase 2–derived reactive oxygen species contribute to long-term potentiation of C-fiber-evoked field potentials in spinal dorsal horn and persistent mirror-image pain following high-frequency stimulus of the sciatic nerve. Pain 2020 161 4 758 772 10.1097/j.pain.0000000000001761 32195784
23 Long H. Zheng H. Ai L. Osman K. Liu Z. Down-regulation of NOX4 expression in dorsal horn of spinal cord could alleviate cancer-induced bone pain in rats by reducing oxidative stress response. Cancer Manag. Res. 2020 12 10929 10938 10.2147/CMAR.S263177 33154672
24 Ji G. Li Z. Neugebauer V. Reactive oxygen species mediate visceral pain-related amygdala plasticity and behaviors. Pain 2015 156 5 825 836 10.1097/j.pain.0000000000000120 25734993
25 Liu Y. Jiang P. Du M. Chen K. Chen A. Wang Y. Cao F. Deng S. Xu Y. Hyperoxia-induced immature brain injury through the TLR4 signaling pathway in newborn mice. Brain Res. 2015 1610 51 60 10.1016/j.brainres.2015.03.021 25801121
26 Diaz F. Garcia S. Padgett K.R. Moraes C.T. A defect in the mitochondrial complex III, but not complex IV, triggers early ROS-dependent damage in defined brain regions. Hum. Mol. Genet. 2012 21 23 5066 5077 10.1093/hmg/dds350 22914734
27 Zhou Y.Q. Liu D.Q. Chen S.P. Sun J. Zhou X.R. Rittner H. Mei W. Tian Y.K. Zhang H.X. Chen F. Ye D.W. Reactive oxygen species scavengers ameliorate mechanical allodynia in a rat model of cancer-induced bone pain. Redox Biol. 2018 14 391 397 10.1016/j.redox.2017.10.011 29055283
28 Yowtak J. Lee K.Y. Kim H.Y. Wang J. Kim H.K. Chung K. Chung J.M. Reactive oxygen species contribute to neuropathic pain by reducing spinal GABA release. Pain 2011 152 4 844 852 10.1016/j.pain.2010.12.034 21296500
29 Yowtak J. Wang J. Kim H.Y. Lu Y. Chung K. Chung J.M. Effect of antioxidant treatment on spinal GABA neurons in a neuropathic pain model in the mouse. Pain 2013 154 11 2469 2476 10.1016/j.pain.2013.07.024 23880056
30 Bittar A. Jun J. La J.H. Wang J. Leem J.W. Chung J.M. Reactive oxygen species affect spinal cell type-specific synaptic plasticity in a model of neuropathic pain. Pain 2017 158 11 2137 2146 10.1097/j.pain.0000000000001014 28708760
31 Gao X. Kim H.K. Mo Chung J. Chung K. Reactive oxygen species (ROS) are involved in enhancement of NMDA-receptor phosphorylation in animal models of pain. Pain 2007 131 3 262 271 10.1016/j.pain.2007.01.011 17317010
32 Fu Q. Shi D. Zhou Y. Zheng H. Xiang H. Tian X. Gao F. Manyande A. Cao F. Tian Y. Ye D. MHC-I promotes apoptosis of GABAergic interneurons in the spinal dorsal horn and contributes to cancer induced bone pain. Exp. Neurol. 2016 286 12 20 10.1016/j.expneurol.2016.09.002 27619625
33 Carrasco C. Naziroǧlu M. Rodríguez A.B. Pariente J.A. Neuropathic pain: Delving into the oxidative origin and the possible implication of transient receptor potential channels. Front. Physiol. 2018 9 95 10.3389/fphys.2018.00095 29491840
34 Ogawa N. Kurokawa T. Mori Y. Sensing of redox status by TRP channels. Cell Calcium 2016 60 2 115 122 10.1016/j.ceca.2016.02.009 26969190
35 Zhou Y.Q. Liu Z. Liu H.Q. Liu D.Q. Chen S.P. Ye D.W. Tian Y.K. Targeting glia for bone cancer pain. Expert Opin. Ther. Targets 2016 20 11 1365 1374 10.1080/14728222.2016.1214716 27428617
36 Zhou Y.Q. Liu Z. Liu Z.H. Chen S.P. Li M. Shahveranov A. Ye D.W. Tian Y.K. Interleukin-6: An emerging regulator of pathological pain. J. Neuroinflammation 2016 13 1 141 10.1186/s12974-016-0607-6 27267059
37 Kim D. You B. Jo E.K. Han S.K. Simon M.I. Lee S.J. NADPH oxidase 2-derived reactive oxygen species in spinal cord microglia contribute to peripheral nerve injury-induced neuropathic pain. Proc. Natl. Acad. Sci. USA 2010 107 33 14851 14856 10.1073/pnas.1009926107 20679217
38 Miao H. Xu J. Xu D. Ma X. Zhao X. Liu L. Nociceptive behavior induced by chemotherapeutic paclitaxel and beneficial role of antioxidative pathways. Physiol. Res. 2019 68 3 491 500 10.33549/physiolres.933939 30433798
39 Chen Y. Qin C. Huang J. Tang X. Liu C. Huang K. Xu J. Guo G. Tong A. Zhou L. The role of astrocytes in oxidative stress of central nervous system: A mixed blessing. Cell Prolif. 2020 53 3 e12781 10.1111/cpr.12781 32035016
40 Zhou Y.Q. Liu D.Q. Chen S.P. Sun J. Wang X.M. Tian Y.K. Wu W. Ye D.W. Minocycline as a promising therapeutic strategy for chronic pain. Pharmacol. Res. 2018 134 305 310 10.1016/j.phrs.2018.07.002 30042091
41 Abais J.M. Xia M. Zhang Y. Boini K.M. Li P.L. Redox regulation of NLRP3 inflammasomes: ROS as trigger or effector? Antioxid. Redox Signal. 2015 22 13 1111 1129 10.1089/ars.2014.5994 25330206
42 Schloss J.M. Colosimo M. Airey C. Masci P.P. Linnane A.W. Vitetta L. Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): A systematic review. Clin. Nutr. 2013 32 6 888 893 10.1016/j.clnu.2013.04.007 23647723
43 Marchesi N. Govoni S. Allegri M. Non‐drug pain relievers active on non‐opioid pain mechanisms. Pain Pract. 2022 22 2 255 275 10.1111/papr.13073 34498362
44 Zorov D.B. Filburn C.R. Klotz L.O. Zweier J.L. Sollott S.J. Reactive oxygen species (ROS)-induced ROS release: A new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J. Exp. Med. 2000 192 7 1001 1014 10.1084/jem.192.7.1001 11015441
45 Fukai T. Ushio-Fukai M. Cross-Talk between NADPH oxidase and mitochondria: Role in ROS signaling and angiogenesis. Cells 2020 9 8 1849 10.3390/cells9081849 32781794
46 Sassetti E. Clausen M.H. Laraia L. Small-molecule inhibitors of reactive oxygen species production. J. Med. Chem. 2021 64 9 5252 5275 10.1021/acs.jmedchem.0c01914 33856791
47 Nunnari J. Suomalainen A. Mitochondria: In sickness and in health. Cell 2012 148 6 1145 1159 10.1016/j.cell.2012.02.035 22424226
48 Zhang B. Pan C. Feng C. Yan C. Yu Y. Chen Z. Guo C. Wang X. Role of mitochondrial reactive oxygen species in homeostasis regulation. Redox Rep. 2022 27 1 45 52 10.1080/13510002.2022.2046423 35213291
49 Murphy M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009 417 1 1 13 10.1042/BJ20081386 19061483
50 Thirupathi A. Pinho R.A. Effects of reactive oxygen species and interplay of antioxidants during physical exercise in skeletal muscles. J. Physiol. Biochem. 2018 74 3 359 367 10.1007/s13105-018-0633-1 29713940
51 Michel H. Behr J. Harrenga A. Kannt A. Cytochrome C oxidase: Structure and spectroscopy. Annu. Rev. Biophys. Biomol. Struct. 1998 27 1 329 356 10.1146/annurev.biophys.27.1.329 9646871
52 Miki T. Mitochondrial complex V(ATP synthase). Jpn. J. Clin. Med. 2002 60 Suppl. 4 154 158 12013840
53 Vercellino I. Sazanov L.A. The assembly, regulation and function of the mitochondrial respiratory chain. Nat. Rev. Mol. Cell Biol. 2022 23 2 141 161 10.1038/s41580-021-00415-0 34621061
54 Sun Q. Zhong W. Zhang W. Zhou Z. Defect of mitochondrial respiratory chain is a mechanism of ROS overproduction in a rat model of alcoholic liver disease: role of zinc deficiency. Am. J. Physiol. Gastrointest. Liver Physiol. 2016 310 3 G205 G214 10.1152/ajpgi.00270.2015 26585415
55 Paradies G. Paradies V. Ruggiero F.M. Petrosillo G. Mitochondrial bioenergetics decay in aging: Beneficial effect of melatonin. Cell. Mol. Life Sci. 2017 74 21 3897 3911 10.1007/s00018-017-2619-5 28785806
56 Joseph E.K. Levine J.D. Mitochondrial electron transport in models of neuropathic and inflammatory pain. Pain 2006 121 1 105 114 10.1016/j.pain.2005.12.010 16472913
57 Trecarichi A. Flatters S.J.L. Mitochondrial dysfunction in the pathogenesis of chemotherapy-induced peripheral neuropathy. Int. Rev. Neurobiol. 2019 145 83 126 10.1016/bs.irn.2019.05.001 31208528
58 Griffiths L.A. Flatters S.J.L. Pharmacological modulation of the mitochondrial electron transport chain in paclitaxel-induced painful peripheral neuropathy. J. Pain 2015 16 10 981 994 10.1016/j.jpain.2015.06.008 26142652
59 Xiao W.H. Bennett G.J. Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin. Pain 2012 153 3 704 709 10.1016/j.pain.2011.12.011 22244441
60 Karu T.I. Multiple roles of cytochrome C oxidase in mammalian cells under action of red and IR-A radiation. IUBMB Life 2010 62 8 607 610 10.1002/iub.359 20681024
61 Hamblin R.M. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys. 2017 4 3 337 361 10.3934/biophy.2017.3.337 28748217
62 Martins D.F. Turnes B.L. Cidral-Filho F.J. Bobinski F. Rosas R.F. Danielski L.G. Petronilho F. Santos A.R.S. Light-emitting diode therapy reduces persistent inflammatory pain: Role of interleukin 10 and antioxidant enzymes. Neuroscience 2016 324 485 495 10.1016/j.neuroscience.2016.03.035 27001179
63 Morris C.R. Brown L.A.S. Reynolds M. Dampier C.D. Lane P.A. Watt A. Kumari P. Harris F. Manoranjithan S. Mendis R.D. Figueroa J. Shiva S. Impact of arginine therapy on mitochondrial function in children with sickle cell disease during vaso-occlusive pain. Blood 2020 136 12 1402 1406 10.1182/blood.2019003672 32384147
64 Qu H. Guo M. Chai H. Wang W. Gao Z. Shi D. Effects of coenzyme Q10 on statin‐induced myopathy: An updated meta‐analysis of randomized controlled trials. J. Am. Heart Assoc. 2018 7 19 e009835 10.1161/JAHA.118.009835 30371340
65 Sawaddiruk P. Apaijai N. Paiboonworachat S. Kaewchur T. Kasitanon N. Jaiwongkam T. Kerdphoo S. Chattipakorn N. Chattipakorn S.C. Coenzyme Q10 supplementation alleviates pain in pregabalin-treated fibromyalgia patients via reducing brain activity and mitochondrial dysfunction. Free Radic. Res. 2019 53 8 901 909 10.1080/10715762.2019.1645955 31387429
66 Khuankaew C. Apaijai N. Sawaddiruk P. Jaiwongkam T. Kerdphoo S. Pongsiriwet S. Tassaneeyakul W. Chattipakorn N. Chattipakorn S.C. Effect of coenzyme Q10 on mitochondrial respiratory proteins in trigeminal neuralgia. Free Radic. Res. 2018 52 4 415 425 10.1080/10715762.2018.1438608 29424256
67 Lauro F. Ilari S. Giancotti L.A. Ventura C.A. Morabito C. Gliozzi M. Malafoglia V. Palma E. Paolino D. Mollace V. Muscoli C. Pharmacological effect of a new idebenone formulation in a model of carrageenan-induced inflammatory pain. Pharmacol. Res. 2016 111 767 773 10.1016/j.phrs.2016.07.043 27480201
68 Montenegro L. Turnaturi R. Parenti C. Pasquinucci L. Idebenone: Novel strategies to improve its systemic and local efficacy. Nanomaterials 2018 8 2 87 10.3390/nano8020087 29401722
69 Cordero M.D. Moreno-Fernández A.M. deMiguel M. Bonal P. Campa F. Jiménez-Jiménez L.M. Ruiz-Losada A. Sánchez-Domínguez B. Sánchez Alcázar J.A. Salviati L. Navas P. Coenzyme Q10 distribution in blood is altered in patients with Fibromyalgia. Clin. Biochem. 2009 42 7-8 732 735 10.1016/j.clinbiochem.2008.12.010 19133251
70 Duncan A.J. Heales S.J.R. Mills K. Eaton S. Land J.M. Hargreaves I.P. Determination of coenzyme Q10 status in blood mononuclear cells, skeletal muscle, and plasma by HPLC with di-propoxy-coenzyme Q10 as an internal standard. Clin. Chem. 2005 51 12 2380 2382 10.1373/clinchem.2005.054643 16306103
71 Wang Y. Hekimi S. Understanding ubiquinone. Trends Cell Biol. 2016 26 5 367 378 10.1016/j.tcb.2015.12.007 26827090
72 Zhao R.Z. Jiang S. Zhang L. Yu Z.B. Mitochondrial electron transport chain, ROS generation and uncoupling (Review). Int. J. Mol. Med. 2019 44 1 3 15 10.3892/ijmm.2019.4188 31115493
73 Wu D. Liu J. Occlusal interference induces oxidative stress and increases the expression of UCP3 in the masseter muscle: A rat model. Arch. Oral Biol. 2019 102 249 255 10.1016/j.archoralbio.2019.04.022 31096116
74 Simonić-Kocijan S. Uhac I. Braut V. Kovac Z. Pavicić D.K. Fugosić V. Urek M.M. Influence of chronic stress and oclusal interference on masseter muscle pain in rat. Coll. Antropol. 2009 33 3 863 866 19860116
75 Micheli L. Testai L. Angeli A. Carrino D. Pacini A. Margiotta F. Flori L. Supuran C.T. Calderone V. Ghelardini C. Di Cesare Mannelli L. Inhibitors of mitochondrial human carbonic anhydrases VA and VB as a therapeutic strategy against paclitaxel-induced neuropathic pain in mice. Int. J. Mol. Sci. 2022 23 11 6229 10.3390/ijms23116229 35682907
76 Price T.O. Sheibani N. Shah G.N. Regulation of high glucose-induced apoptosis of brain pericytes by mitochondrial CA VA: A specific target for prevention of diabetic cerebrovascular pathology. Biochim. Biophys. Acta Mol. Basis Dis. 2017 1863 4 929 935 10.1016/j.bbadis.2017.01.025 28131914
77 Willemen H.L.D.M. Kavelaars A. Prado J. Maas M. Versteeg S. Nellissen L.J.J. Tromp J. Gonzalez Cano R. Zhou W. Jakobsson M.E. Małecki J. Posthuma G. Habib A.M. Heijnen C.J. Falnes P.Ø. Eijkelkamp N. Identification of FAM173B as a protein methyltransferase promoting chronic pain. PLoS Biol. 2018 16 2 e2003452 10.1371/journal.pbio.2003452 29444090
78 Małecki J.M. Willemen H.L.D.M. Pinto R. Ho A.Y.Y. Moen A. Kjønstad I.F. Burgering B.M.T. Zwartkruis F. Eijkelkamp N. Falnes P.Ø. Lysine methylation by the mitochondrial methyltransferase FAM173B optimizes the function of mitochondrial ATP synthase. J. Biol. Chem. 2019 294 4 1128 1141 10.1074/jbc.RA118.005473 30530489
79 Sulem P. Helgason H. Oddson A. Stefansson H. Gudjonsson S.A. Zink F. Hjartarson E. Sigurdsson G.T. Jonasdottir A. Jonasdottir A. Sigurdsson A. Magnusson O.T. Kong A. Helgason A. Holm H. Thorsteinsdottir U. Masson G. Gudbjartsson D.F. Stefansson K. Identification of a large set of rare complete human knockouts. Nat. Genet. 2015 47 5 448 452 10.1038/ng.3243 25807282
80 Flatters S.J.L. Dougherty P.M. Colvin L.A. Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): A narrative review. Br. J. Anaesth. 2017 119 4 737 749 10.1093/bja/aex229 29121279
81 Kong H. Jiang C.Y. Hu L. Teng P. Zhang Y. Pan X.X. Sun X.D. Liu W.T. Morphine induces dysfunction of PINK1/Parkin-mediated mitophagy in spinal cord neurons implying involvement in antinociceptive tolerance. J. Mol. Cell Biol. 2019 11 12 1056 1068 10.1093/jmcb/mjz002 30698724
82 Fischer F. Hamann A. Osiewacz H.D. Mitochondrial quality control: An integrated network of pathways. Trends Biochem. Sci. 2012 37 7 284 292 10.1016/j.tibs.2012.02.004 22410198
83 Li W. Cheng H. Li G. Zhang L. Mitochondrial damage and the road to exhaustion. Cell Metab. 2020 32 6 905 907 10.1016/j.cmet.2020.11.004 33264601
84 Ul Fatima N. Ananthanarayanan V. Mitochondrial movers and shapers: Recent insights into regulators of fission, fusion and transport. Curr. Opin. Cell Biol. 2023 80 102150 10.1016/j.ceb.2022.102150 36580830
85 Luo T.T. Dai C.Q. Wang J.Q. Wang Z.M. Yang Y. Zhang K.L. Wu F.F. Yang Y.L. Wang Y.Y. Drp1 is widely, yet heterogeneously, distributed in the mouse central nervous system. Mol. Brain 2020 13 1 90 10.1186/s13041-020-00628-y 32522292
86 Yu T. Sheu S.S. Robotham J.L. Yoon Y. Mitochondrial fission mediates high glucose-induced cell death through elevated production of reactive oxygen species. Cardiovasc. Res. 2008 79 2 341 351 10.1093/cvr/cvn104 18440987
87 Sun H. Li X. Chen X. Xiong Y. Cao Y. Wang Z. Drp1 activates ROS/HIF-1α/EZH2 and triggers mitochondrial fragmentation to deteriorate hypercalcemia-associated neuronal injury in mouse model of chronic kidney disease. J. Neuroinflammation 2022 19 1 213 10.1186/s12974-022-02542-7 36050772
88 Zhou S. Pan Y. Zhang Y. Gu L. Ma L. Xu Q. Wang W. Sun J. Antisense oligodeoxynucleotides against dynamin-related protein 1 reduce remifentanil-induced hyperalgesia by modulating spinal N-methyl-D-aspartate receptor expression in rats. Korean J. Pain 2023 36 3 316 327 10.3344/kjp.22398 37183652
89 Sheffer R. Douiev L. Edvardson S. Shaag A. Tamimi K. Soiferman D. Meiner V. Saada A. Postnatal microcephaly and pain insensitivity due to a de novo heterozygous DNM1L mutation causing impaired mitochondrial fission and function. Am. J. Med. Genet. A. 2016 170 6 1603 1607 10.1002/ajmg.a.37624 26992161
90 Kanda H. Liu S. Iida T. Yi H. Huang W. Levitt R.C. Lubarsky D.A. Candiotti K.A. Hao S. Inhibition of mitochondrial fission protein reduced mechanical allodynia and suppressed spinal mitochondrial superoxide induced by perineural human immunodeficiency virus gp120 in rats. Anesth. Analg. 2016 122 1 264 272 10.1213/ANE.0000000000000962 26418124
91 Zhan L. Li R. Sun Y. Dou M. Yang W. He S. Zhang Y. Effect of mito-TEMPO, a mitochondria-targeted antioxidant, in rats with neuropathic pain. Neuroreport 2018 29 15 1275 1281 10.1097/WNR.0000000000001105 30052549
92 Flippo K.H. Strack S. Mitochondrial dynamics in neuronal injury, development and plasticity. J. Cell Sci. 2017 130 4 jcs.171017 10.1242/jcs.171017 28154157
93 Xie M. Cheng M. Wang B. Jiao M. Yu L. Zhu H. 2-Bromopalmitate attenuates inflammatory pain by maintaining mitochondrial fission/fusion balance and function. Acta Biochim. Biophys. Sin. 2020 53 1 72 84 10.1093/abbs/gmaa150 33253369
94 Dong Z.B. Wang Y.J. Cheng M.L. Wang B.J. Lu H. Zhu H.L. Liu L. Xie M. 2-Bromopalmitate decreases spinal inflammation and attenuates oxaliplatin-induced neuropathic pain via reducing Drp1-mediated mitochondrial dysfunction. PLoS One 2022 17 10 e0275428 10.1371/journal.pone.0275428 36315519
95 Zhang K.L. Li S.J. Pu X.Y. Wu F.F. Liu H. Wang R.Q. Liu B.Z. Li Z. Li K.F. Qian N.S. Yang Y.L. Yuan H. Wang Y.Y. Targeted up-regulation of Drp1 in dorsal horn attenuates neuropathic pain hypersensitivity by increasing mitochondrial fission. Redox Biol. 2022 49 102216 10.1016/j.redox.2021.102216 34954498
96 Li P.A. Hou X. Hao S. Mitochondrial biogenesis in neurodegeneration. J. Neurosci. Res. 2017 95 10 2025 2029 10.1002/jnr.24042 28301064
97 Witte M.E. Nijland P.G. Drexhage J.A.R. Gerritsen W. Geerts D. van het Hof B. Reijerkerk A. de Vries H.E. van der Valk P. van Horssen J. Reduced expression of PGC-1α partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex. Acta Neuropathol. 2013 125 2 231 243 10.1007/s00401-012-1052-y 23073717
98 Sun J. Li J.Y. Zhang L.Q. Li D.Y. Wu J.Y. Gao S.J. Liu D.Q. Zhou Y.Q. Mei W. Nrf2 activation attenuates chronic constriction injury-induced neuropathic pain via induction of pgc-1α-mediated mitochondrial biogenesis in the spinal cord. Oxid. Med. Cell. Longev. 2021 2021 1 17 10.1155/2021/9577874 34721761
99 Chen N. Ge M.M. Li D.Y. Wang X.M. Liu D.Q. Ye D.W. Tian Y.K. Zhou Y.Q. Chen J.P. β2-adrenoreceptor agonist ameliorates mechanical allodynia in paclitaxel-induced neuropathic pain via induction of mitochondrial biogenesis. Biomed. Pharmacother. 2021 144 112331 10.1016/j.biopha.2021.112331 34673421
100 Zhang L.Q. Zhou Y.Q. Li J.Y. Sun J. Zhang S. Wu J.Y. Gao S.J. Tian X.B. Mei W. 5-HT1F receptor agonist ameliorates mechanical allodynia in neuropathic pain via induction of mitochondrial biogenesis and suppression of neuroinflammation. Front. Pharmacol. 2022 13 834570 10.3389/fphar.2022.834570 35308244
101 Zhou Y. Liu D. Chen S. Chen N. Sun J. Wang X. Cao F. Tian Y. Ye D. Nrf2 activation ameliorates mechanical allodynia in paclitaxel-induced neuropathic pain. Acta Pharmacol. Sin. 2020 41 8 1041 1048 10.1038/s41401-020-0394-6 32203087
102 Zhou Y.Q. Mei W. Tian X.B. Tian Y.K. Liu D.Q. Ye D.W. The therapeutic potential of Nrf2 inducers in chronic pain: Evidence from preclinical studies. Pharmacol. Ther. 2021 225 107846 10.1016/j.pharmthera.2021.107846 33819559
103 Gureev A.P. Shaforostova E.A. Popov V.N. Regulation of mitochondrial biogenesis as a way for active longevity: Interaction between the Nrf2 and PGC-1α signaling pathways. Front. Genet. 2019 10 435 10.3389/fgene.2019.00435 31139208
104 Santin Y. Resta J. Parini A. Mialet-Perez J. Monoamine oxidases in age-associated diseases: New perspectives for old enzymes. Ageing Res. Rev. 2021 66 101256 10.1016/j.arr.2021.101256 33434685
105 Park S.E. Neupane C. Noh C. Sharma R. Shin H.J. Pham T.L. Lee G.S. Park K.D. Lee C.J. Kang D.W. Lee S.Y. Kim H.W. Park J.B. Antiallodynic effects of KDS2010, a novel MAO-B inhibitor, via ROS-GABA inhibitory transmission in a paclitaxel-induced tactile hypersensitivity model. Mol. Brain 2022 15 1 41 10.1186/s13041-022-00924-9 35526002
106 Yao X. Li L. Kandhare A.D. Mukherjee-Kandhare A.A. Bodhankar S.L. Attenuation of reserpine-induced fibromyalgia via ROS and serotonergic pathway modulation by fisetin, a plant flavonoid polyphenol. Exp. Ther. Med. 2020 19 2 1343 1355 32010308
107 Jóźwiak-Bębenista M. Wiktorowska-Owczarek A. Kowalczyk E. Beta-adrenoceptor-mediated cyclic AMP signal in different types of cultured nerve cells in normoxic and hypoxic conditions. Mol. Biol. 2016 50 5 838 846 27830686
108 Zhang H. Kong Q. Wang J. Jiang Y. Hua H. Complex roles of cAMP–PKA–CREB signaling in cancer. Exp. Hematol. Oncol. 2020 9 1 32 10.1186/s40164-020-00191-1 33292604
109 Chen S.P. Sun J. Zhou Y.Q. Cao F. Braun C. Luo F. Ye D.W. Tian Y.K. Sinomenine attenuates cancer-induced bone pain via suppressing microglial JAK2/STAT3 and neuronal CAMKII/CREB cascades in rat models. Mol. Pain 2018 14 10.1177/1744806918793232 30027795
110 Iida T. Yi H. Liu S. Huang W. Kanda H. Lubarsky D.A. Hao S. Spinal CPEB-mtROS-CBP signaling pathway contributes to perineural HIV gp120 with ddC-related neuropathic pain in rats. Exp. Neurol. 2016 281 17 27 10.1016/j.expneurol.2016.04.012 27090160
111 Vanfleteren L. Fabbri L.M. Papi A. Petruzzelli S. Celli B. Triple therapy (ICS/LABA/LAMA) in COPD: Time for a reappraisal. Int. J. Chron. Obstruct. Pulmon. Dis. 2018 13 3971 3981 10.2147/COPD.S185975 30587953
112 Lamb Y.N. Lasmiditan: First Approval. Drugs 2019 79 18 1989 1996 10.1007/s40265-019-01225-7 31749059
113 Gottlieb R.A. Carreira R.S. Autophagy in health and disease. 5. Mitophagy as a way of life. Am. J. Physiol. Cell Physiol. 2010 299 2 C203 C210 10.1152/ajpcell.00097.2010 20357180
114 Wang D.B. Garden G.A. Kinoshita C. Wyles C. Babazadeh N. Sopher B. Kinoshita Y. Morrison R.S. Declines in Drp1 and parkin expression underlie DNA damage-induced changes in mitochondrial length and neuronal death. J. Neurosci. 2013 33 4 1357 1365 10.1523/JNEUROSCI.3365-12.2013 23345212
115 Yamashita A. Matsuoka Y. Matsuda M. Kawai K. Sawa T. Amaya F. Dysregulation of p53 and parkin induce mitochondrial dysfunction and leads to the diabetic neuropathic pain. Neuroscience 2019 416 9 19 10.1016/j.neuroscience.2019.07.045 31377450
116 Krukowski K. Nijboer C.H. Huo X. Kavelaars A. Heijnen C.J. Prevention of chemotherapy-induced peripheral neuropathy by the small-molecule inhibitor pifithrin-μ. Pain 2015 156 11 2184 2192 10.1097/j.pain.0000000000000290 26473292
117 Maj M.A. Ma J. Krukowski K.N. Kavelaars A. Heijnen C.J. Inhibition of mitochondrial p53 accumulation by PFT-μ prevents cisplatin-induced peripheral neuropathy. Front. Mol. Neurosci. 2017 10 108 10.3389/fnmol.2017.00108 28458631
118 Leu J.I.J. Pimkina J. Frank A. Murphy M.E. George D.L. A small molecule inhibitor of inducible heat shock protein 70. Mol. Cell 2009 36 1 15 27 10.1016/j.molcel.2009.09.023 19818706
119 Shang X. Lin K. Zhang Y. Li M. Xu J. Chen K. Zhu P. Yu R. Mst1 deletion reduces septic cardiomyopathy via activating Parkin‐related mitophagy. J. Cell. Physiol. 2020 235 1 317 327 10.1002/jcp.28971 31215035
120 Huang Z. Xiao P.Y. Chen J.Y. Zeng Q. Huang B.X. Yu J. Liao S.J. Mammalian sterile 20-like kinase 1 mediates neuropathic pain associated with its effects on regulating mitophagy in schwann cells. Oxid. Med. Cell. Longev. 2022 2022 1 17 10.1155/2022/3458283 35656021
121 Ilari S. Giancotti L.A. Lauro F. Dagostino C. Gliozzi M. Malafoglia V. Sansone L. Palma E. Tafani M. Russo M.A. Tomino C. Fini M. Salvemini D. Mollace V. Muscoli C. Antioxidant modulation of sirtuin 3 during acute inflammatory pain: The ROS control. Pharmacol. Res. 2020 157 104851 10.1016/j.phrs.2020.104851 32423865
122 Jeninga E.H. Schoonjans K. Auwerx J. Reversible acetylation of PGC-1: connecting energy sensors and effectors to guarantee metabolic flexibility. Oncogene 2010 29 33 4617 4624 10.1038/onc.2010.206 20531298
123 Zahedi E. Sadr S.S. Sanaeierad A. Roghani M. Valproate-induced murine autism spectrum disorder is associated with dysfunction of amygdala parvalbumin interneurons and downregulation of AMPK/SIRT1/PGC1α signaling. Metab. Brain Dis. 2023 38 6 2093 2103 10.1007/s11011-023-01227-1 37184727
124 Li X. Yang S. Wang L. Liu P. Zhao S. Li H. Jiang Y. Guo Y. Wang X. Resveratrol inhibits paclitaxel-induced neuropathic pain by the activation of PI3K/Akt and SIRT1/PGC1α pathway. J. Pain Res. 2019 12 879 890 10.2147/JPR.S185873 30881098
125 Hao C. Ma B. Gao N. Jin T. Liu X. Translocator protein (TSPO) alleviates neuropathic pain by activating spinal autophagy and nuclear SIRT1/PGC-1α signaling in a rat L5 SNL model. J. Pain Res. 2022 15 767 778 10.2147/JPR.S359397 35356265
126 Cheng Y.Y. Kao C.L. Ma H.I. Hung C.H. Wang C.T. Liu D.H. Chen P.Y. Tsai K.L. SIRT1-related inhibition of pro-inflammatory responses and oxidative stress are involved in the mechanism of nonspecific low back pain relief after exercise through modulation of Toll-like receptor 4. J. Biochem. 2015 158 4 299 308 10.1093/jb/mvv041 25922201
127 Tseng A.H.H. Shieh S.S. Wang D.L. SIRT3 deacetylates FOXO3 to protect mitochondria against oxidative damage. Free Radic. Biol. Med. 2013 63 222 234 10.1016/j.freeradbiomed.2013.05.002 23665396
128 Cheng A. Yang Y. Zhou Y. Maharana C. Lu D. Peng W. Liu Y. Wan R. Marosi K. Misiak M. Bohr V.A. Mattson M.P. Mitochondrial SIRT3 mediates adaptive responses of neurons to exercise and metabolic and excitatory challenges. Cell Metab. 2016 23 1 128 142 10.1016/j.cmet.2015.10.013 26698917
129 Zhou C. Zhang Y. Jiao X. Wang G. Wang R. Wu Y. SIRT3 alleviates neuropathic pain by deacetylating FoxO3a in the spinal dorsal horn of diabetic model rats. Reg. Anesth. Pain Med. 2021 46 1 49 56 10.1136/rapm-2020-101918 33127810
130 Fritz K.S. Galligan J.J. Smathers R.L. Roede J.R. Shearn C.T. Reigan P. Petersen D.R. 4-Hydroxynonenal inhibits SIRT3 via thiol-specific modification. Chem. Res. Toxicol. 2011 24 5 651 662 10.1021/tx100355a 21449565
131 Turnley A.M. Stapleton D. Mann R.J. Witters L.A. Kemp B.E. Bartlett P.F. Cellular distribution and developmental expression of AMP-activated protein kinase isoforms in mouse central nervous system. J. Neurochem. 1999 72 4 1707 1716 10.1046/j.1471-4159.1999.721707.x 10098881
132 Herzig S. Shaw R.J. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat. Rev. Mol. Cell Biol. 2018 19 2 121 135 10.1038/nrm.2017.95 28974774
133 Ge M.M. Li D.Y. Wang L. Zhang L.Q. Liu D.Q. Tian Y.K. Ye D.W. Liu Z.H. Zhou Y.Q. Yang H. Naringenin promoted spinal microglia M2 polarization in rat model of cancer-induced bone pain via regulating AMPK/PGC-1α signaling axis. Biomed. Pharmacother. 2022 149 112912 10.1016/j.biopha.2022.112912 35856853
134 Xu W. Mo J. Ocak U. Travis Z.D. Enkhjargal B. Zhang T. Wu P. Peng J. Li T. Zuo Y. Shao A. Tang J. Zhang J. Zhang J.H. Activation of melanocortin 1 receptor attenuates early brain injury in a rat model of subarachnoid hemorrhage viathe suppression of neuroinflammation through AMPK/TBK1/NF-κB pathway in rats. Neurotherapeutics 2020 17 1 294 308 10.1007/s13311-019-00772-x 31486022
135 Han C. Zheng J. Sun L. Yang H. Cao Z. Zhang X. Zheng L. Zhen X. The oncometabolite 2-hydroxyglutarate inhibits microglial activation via the AMPK/mTOR/NF-κB pathway. Acta Pharmacol. Sin. 2019 40 10 1292 1302 10.1038/s41401-019-0225-9 31015738
136 Song J. Zhang W. Wang J. Yang H. Zhao X. Zhou Q. Wang H. Li L. Du G. Activation of Nrf2 signaling by salvianolic acid C attenuates NF κB mediated inflammatory response both in vivo and in vitro. Int. Immunopharmacol. 2018 63 299 310 10.1016/j.intimp.2018.08.004 30142530
137 Morgan M.J. Liu Z. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res. 2011 21 1 103 115 10.1038/cr.2010.178 21187859
138 Sun J. Zhou Y. Xu B. Li J. Zhang L. Li D. Zhang S. Wu J. Gao S. Ye D. Mei W. STING/NF-κB/IL-6-mediated inflammation in microglia contributes to spared nerve injury (SNI)-induced pain initiation. J. Neuroimmune Pharmacol. 2022 17 3-4 453 469 10.1007/s11481-021-10031-6 34727296
139 Maixner D.W. Yan X. Gao M. Yadav R. Weng H.R. Adenosine monophosphate–activated protein kinase regulates interleukin-1β expression and glial glutamate transporter function in rodents with neuropathic pain. Anesthesiology 2015 122 6 1401 1413 10.1097/ALN.0000000000000619 25710409
140 Maixner D.W. Yan X. Hooks S.B. Weng H.R. AMPKα1 knockout enhances nociceptive behaviors and spinal glutamatergic synaptic activities via production of reactive oxygen species in the spinal dorsal horn. Neuroscience 2016 326 158 169 10.1016/j.neuroscience.2016.03.061 27058143
141 Yang H. Wang Y. Zhen S. Wang B. Jiao M. Liu L. Li D. Zhu H. Xie M. AMPK activation attenuates cancer-induced bone pain by reducing mitochondrial dysfunction-mediated neuroinflammation. Acta Biochim. Biophys. Sin. 2023 55 3 460 471 10.3724/abbs.2023039 36971458
142 Chen S.P. Zhou Y.Q. Wang X.M. Sun J. Cao F. HaiSam, S.; Ye, D.W.; Tian, Y.K. Pharmacological inhibition of the NLRP3 inflammasome as a potential target for cancer-induced bone pain. Pharmacol. Res. 2019 147 104339 10.1016/j.phrs.2019.104339 31276771
143 Haddad M. Eid S. Harb F. Massry M.E.L. Azar S. Sauleau E.A. Eid A.A. Activation of 20-HETE synthase triggers oxidative injury and peripheral nerve damage in type 2 diabetic mice. J. Pain 2022 23 8 1371 1388 10.1016/j.jpain.2022.02.011 35339661
144 Wu C. Chen H. Zhuang R. Zhang H. Wang Y. Hu X. Xu Y. Li J. Li Y. Wang X. Xu H. Ni W. Zhou K. Betulinic acid inhibits pyroptosis in spinal cord injury by augmenting autophagy via the AMPK-mTOR-TFEB signaling pathway. Int. J. Biol. Sci. 2021 17 4 1138 1152 10.7150/ijbs.57825 33867836
145 Holmström K.M. Finkel T. Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat. Rev. Mol. Cell Biol. 2014 15 6 411 421 10.1038/nrm3801 24854789
146 Cross A.R. Segal A.W. The NADPH oxidase of professional phagocytes-prototype of the NOX electron transport chain systems. Biochim. Biophys. Acta Bioenerg. 2004 1657 1 1 22 10.1016/j.bbabio.2004.03.008 15238208
147 Kim J.S. Yeo S. Shin D.G. Bae Y.S. Lee J.J. Chin B.R. Lee C.H. Baek S.H. Glycogen synthase kinase 3β and β-catenin pathway is involved in toll-like receptor 4-mediated NADPH oxidase 1 expression in macrophages. FEBS J. 2010 277 13 2830 2837 10.1111/j.1742-4658.2010.07700.x 20528914
148 Ibi M. Matsuno K. Matsumoto M. Sasaki M. Nakagawa T. Katsuyama M. Iwata K. Zhang J. Kaneko S. Yabe-Nishimura C. Involvement of NOX1/NADPH oxidase in morphine-induced analgesia and tolerance. J. Neurosci. 2011 31 49 18094 18103 10.1523/JNEUROSCI.4136-11.2011 22159121
149 Ibi M. Matsuno K. Shiba D. Katsuyama M. Iwata K. Kakehi T. Nakagawa T. Sango K. Shirai Y. Yokoyama T. Kaneko S. Saito N. Yabe-Nishimura C. Reactive oxygen species derived from NOX1/NADPH oxidase enhance inflammatory pain. J. Neurosci. 2008 28 38 9486 9494 10.1523/JNEUROSCI.1857-08.2008 18799680
150 Kumar S. Vinayak M. NADPH oxidase1 inhibition leads to regression of central sensitization during formalin induced acute nociception via attenuation of ERK1/2-NFκB signaling and glial activation. Neurochem. Int. 2020 134 104652 10.1016/j.neuint.2019.104652 31891736
151 Song Z. Xiong B. Zheng H. Manyande A. Guan X. Cao F. Ren L. Zhou Y. Ye D. Tian Y. STAT1 as a downstream mediator of ERK signaling contributes to bone cancer pain by regulating MHC II expression in spinal microglia. Brain Behav. Immun. 2017 60 161 173 10.1016/j.bbi.2016.10.009 27742579
152 Ibi M. Liu J. Arakawa N. Kitaoka S. Kawaji A. Matsuda K. Iwata K. Matsumoto M. Katsuyama M. Zhu K. Teramukai S. Furuyashiki T. Yabe-Nishimura C. Depressive-Like Behaviors Are Regulated by NOX1/NADPH Oxidase by Redox Modification of NMDA Receptor 1. J. Neurosci. 2017 37 15 4200 4212 10.1523/JNEUROSCI.2988-16.2017 28314819
153 Finnerup N.B. Kuner R. Jensen T.S. Neuropathic Pain: From mechanisms to treatment. Physiol. Rev. 2021 101 1 259 301 10.1152/physrev.00045.2019 32584191
154 Kallenborn-Gerhardt W. Hohmann S.W. Syhr K.M.J. Schröder K. Sisignano M. Weigert A. Lorenz J.E. Lu R. Brüne B. Brandes R.P. Geisslinger G. Schmidtko A. Nox2-dependent signaling between macrophages and sensory neurons contributes to neuropathic pain hypersensitivity. Pain 2014 155 10 2161 2170 10.1016/j.pain.2014.08.013 25139590
155 Sabirzhanov B. Li Y. Coll-Miro M. Matyas J.J. He J. Kumar A. Ward N. Yu J. Faden A.I. Wu J. Inhibition of NOX2 signaling limits pain-related behavior and improves motor function in male mice after spinal cord injury: Participation of IL-10/miR-155 pathways. Brain Behav. Immun. 2019 80 73 87 10.1016/j.bbi.2019.02.024 30807841
156 De Logu F. Nassini R. Materazzi S. Carvalho Gonçalves M. Nosi D. Rossi Degl’Innocenti, D.; Marone, I.M.; Ferreira, J.; Li Puma, S.; Benemei, S.; Trevisan, G.; Souza Monteiro de Araújo, D.; Patacchini, R.; Bunnett, N.W.; Geppetti, P. Schwann cell TRPA1 mediates neuroinflammation that sustains macrophage-dependent neuropathic pain in mice. Nat. Commun. 2017 8 1 1887 10.1038/s41467-017-01739-2 29192190
157 Hackel D. Pflücke D. Neumann A. Viebahn J. Mousa S. Wischmeyer E. Roewer N. Brack A. Rittner H.L. The connection of monocytes and reactive oxygen species in pain. PLoS One 2013 8 5 e63564 10.1371/journal.pone.0063564 23658840
158 Doyle T. Esposito E. Bryant L. Cuzzocrea S. Salvemini D. NADPH-oxidase 2 activation promotes opioid-induced antinociceptive tolerance in mice. Neuroscience 2013 241 1 9 10.1016/j.neuroscience.2013.02.042 23454539
159 Roos D. Chronic granulomatous disease. Methods Mol. Biol. 2019 1982 531 542 10.1007/978-1-4939-9424-3_32 31172494
160 Geis C. Geuss E. Sommer C. Schmidt H.H.H.W. Kleinschnitz C. NOX4 is an early initiator of neuropathic pain. Exp. Neurol. 2017 288 94 103 10.1016/j.expneurol.2016.11.008 27856286
161 Wack G. Metzner K. Kuth M.S. Wang E. Bresnick A. Brandes R.P. Schröder K. Wittig I. Schmidtko A. Kallenborn-Gerhardt W. Nox4-dependent upregulation of S100A4 after peripheral nerve injury modulates neuropathic pain processing. Free Radic. Biol. Med. 2021 168 155 167 10.1016/j.freeradbiomed.2021.03.021 33789124
162 Vendrov A.E. Madamanchi N.R. Niu X.L. Molnar K.C. Runge M. Szyndralewiez C. Page P. Runge M.S. NADPH oxidases regulate CD44 and hyaluronic acid expression in thrombin-treated vascular smooth muscle cells and in atherosclerosis. J. Biol. Chem. 2010 285 34 26545 26557 10.1074/jbc.M110.143917 20558727
163 Eid S.A. El Massry M. Hichor M. Haddad M. Grenier J. Dia B. Barakat R. Boutary S. Chanal J. Aractingi S. Wiesel P. Szyndralewiez C. Azar S.T. Boitard C. Zaatari G. Eid A.A. Massaad C. Targeting the NADPH oxidase-4 and liver X receptor pathway preserves schwann cell integrity in diabetic mice. Diabetes 2020 69 3 448 464 10.2337/db19-0517 31882567
164 Zhou Y.Q. Chen S.P. Liu D.Q. Manyande A. Zhang W. Yang S.B. Xiong B.R. Fu Q.C. Song Z. Rittner H. Ye D.W. Tian Y.K. The role of spinal GABAB receptors in cancer-induced bone pain in rats. J. Pain 2017 18 8 933 946 10.1016/j.jpain.2017.02.438 28323246
165 Takeya R. Ueno N. Kami K. Taura M. Kohjima M. Izaki T. Nunoi H. Sumimoto H. Novel human homologues of p47 and p67 participate in activation of superoxide-producing NADPH oxidases. J. Biol. Chem. 2015 290 10 6003 10.1074/jbc.A114.212856 25750260
166 Brandes R.P. Weissmann N. Schröder K. Nox family NADPH oxidases: Molecular mechanisms of activation. Free Radic. Biol. Med. 2014 76 208 226 10.1016/j.freeradbiomed.2014.07.046 25157786
167 Chocry M. Leloup L. The NADPH oxidase family and its inhibitors. Antioxid. Redox Signal. 2020 33 5 332 353 10.1089/ars.2019.7915 31826639
168 Takeya R. Ueno N. Kami K. Taura M. Kohjima M. Izaki T. Nunoi H. Sumimoto H. Novel human homologues of p47phox and p67phox participate in activation of superoxide-producing NADPH oxidases. J. Biol. Chem. 2003 278 27 25234 25246 10.1074/jbc.M212856200 12716910
169 Cheng G. Ritsick D. Lambeth J.D. Nox3 Regulation by NOXO1, p47, and p67. J. Biol. Chem. 2004 279 33 34250 34255 10.1074/jbc.M400660200 15181005
170 Ambruso D.R. Knall C. Abell A.N. Panepinto J. Kurkchubasche A. Thurman G. Gonzalez-Aller C. Hiester A. deBoer M. Harbeck R.J. Oyer R. Johnson G.L. Roos D. Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation. Proc. Natl. Acad. Sci. USA 2000 97 9 4654 4659 10.1073/pnas.080074897 10758162
171 Roos D. de Boer M. Kuribayashi F. Meischl C. Weening R.S. Segal A.W. Ahlin A. Nemet K. Hossle J.P. Bernatowska-Matuszkiewicz E. Middleton-Price H. Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Blood 1996 87 5 1663 1681 10.1182/blood.V87.5.1663.1663 8634410
172 Csányi G. Cifuentes-Pagano E. Al Ghouleh I. Ranayhossaini D.J. Egaña L. Lopes L.R. Jackson H.M. Kelley E.E. Pagano P.J. Nox2 B-loop peptide, Nox2ds, specifically inhibits the NADPH oxidase Nox2. Free Radic. Biol. Med. 2011 51 6 1116 1125 10.1016/j.freeradbiomed.2011.04.025 21586323
173 Hodge R.G. Ridley A.J. Regulating Rho GTPases and their regulators. Nat. Rev. Mol. Cell Biol. 2016 17 8 496 510 10.1038/nrm.2016.67 27301673
174 Acevedo A. González-Billault C. Crosstalk between Rac1-mediated actin regulation and ROS production. Free Radic. Biol. Med. 2018 116 101 113 10.1016/j.freeradbiomed.2018.01.008 29330095
175 Price M.O. Atkinson S.J. Knaus U.G. Dinauer M.C. Rac activation induces NADPH oxidase activity in transgenic COSphox cells, and the level of superoxide production is exchange factor-dependent. J. Biol. Chem. 2002 277 21 19220 19228 10.1074/jbc.M200061200 11896053
176 Tan A.M. Samad O.A. Liu S. Bandaru S. Zhao P. Waxman S.G. Burn injury-induced mechanical allodynia is maintained by Rac1-regulated dendritic spine dysgenesis. Exp. Neurol. 2013 248 509 519 10.1016/j.expneurol.2013.07.017 23933578
177 Chen Z. Zhang S. Nie B. Huang J. Han Z. Chen X. Bai X. Ouyang H. Distinct roles of srGAP3‐Rac1 in the initiation and maintenance phases of neuropathic pain induced by paclitaxel. J. Physiol. 2020 598 12 2415 2430 10.1113/JP279525 32237255
178 Tell G. Damante G. Caldwell D. Kelley M.R. The intracellular localization of APE1/Ref-1: More than a passive phenomenon? Antioxid. Redox Signal. 2005 7 3-4 367 384 10.1089/ars.2005.7.367 15706084
179 Angkeow P. Deshpande S.S. Qi B. Liu Y-X. Park Y.C. Jeon B.H. Ozaki M. Irani K. Redox factor-1: An extra-nuclear role in the regulation of endothelial oxidative stress and apoptosis. Cell Death Differ. 2002 9 7 717 725 10.1038/sj.cdd.4401025 12058277
180 Zaky A. Bouali-Benazzouz R. Favereaux A. Tell G. Landry M. APE1/Ref-1 redox function contributes to inflammatory pain sensitization. Exp. Neurol. 2018 307 1 11 10.1016/j.expneurol.2018.05.014 29772245
181 Santulli G. Lewis D. des Georges A. Marks A.R. Frank J. Ryanodine receptor structure and function in health and disease. Subcell. Biochem. 2018 87 329 352 10.1007/978-981-10-7757-9_11 29464565
182 Jin M. Guan C. Jiang Y. Chen G. Zhao C. Cui K. Song Y. Wu C. Poo M. Yuan X. Ca2+-dependent regulation of rho GTPases triggers turning of nerve growth cones. J. Neurosci. 2005 25 9 2338 2347 10.1523/JNEUROSCI.4889-04.2005 15745960
183 Liao B. Zhang Y. Sun H. Ma B. Qian J. Ryanodine receptor 2 plays a critical role in spinal cord injury via induction of oxidative stress. Cell. Physiol. Biochem. 2016 38 3 1129 1137 10.1159/000443063 26963898
184 Wilson C. Muñoz-Palma E. Henríquez D.R. Palmisano I. Núñez M.T. Di Giovanni S. González-Billault C. A feed-forward mechanism involving the NOX complex and RyR-mediated Ca2+ release during axonal specification. J. Neurosci. 2016 36 43 11107 11119 10.1523/JNEUROSCI.1455-16.2016 27798190
185 Sanmartín C.D. Paula-Lima A.C. García A. Barattini P. Hartel S. Núñez M.T. Hidalgo C. Ryanodine receptor-mediated Ca2+ release underlies iron-induced mitochondrial fission and stimulates mitochondrial Ca2+ uptake in primary hippocampal neurons. Front. Mol. Neurosci. 2014 7 13 24653672
186 Godai K. Takahashi K. Kashiwagi Y. Liu C.H. Yi H. Liu S. Dong C. Lubarsky D.A. Hao S. Ryanodine receptor to mitochondrial reactive oxygen species pathway plays an important role in chronic human immunodeficiency virus gp120MN-induced neuropathic pain in rats. Anesth. Analg. 2019 129 1 276 286 10.1213/ANE.0000000000003916 30507840
187 Fridolfsson H.N. Roth D.M. Insel P.A. Patel H.H. Regulation of intracellular signaling and function by caveolin. FASEB J. 2014 28 9 3823 3831 10.1096/fj.14-252320 24858278
188 Zhang Y. Peng F. Gao B. Ingram A.J. Krepinsky J.C. Mechanical strain-induced RhoA activation requires NADPH oxidase-mediated ROS generation in caveolae. Antioxid. Redox Signal. 2010 13 7 959 973 10.1089/ars.2009.2908 20380579
189 Chen J.L. Lu J.H. Xie C.S. Shen Y.J. Wang J.W. Ye X.Y. Zhang M.B. Jia G.L. Tao Y.X. Li J. Cao H. Caveolin-1 in spinal cord modulates type-2 diabetic neuropathic pain through the Rac1/NOX2/NR2B signaling pathway. Am. J. Transl. Res. 2020 12 5 1714 1727 32509171
190 El-Benna J. Dang P.M.C. Gougerot-Pocidalo M.A. Marie J.C. Braut-Boucher F. p47phox, the phagocyte NADPH oxidase/NOX2 organizer: Structure, phosphorylation and implication in diseases. Exp. Mol. Med. 2009 41 4 217 225 10.3858/emm.2009.41.4.058 19372727
191 Zhao W.C. Zhang B. Liao M.J. Zhang W.X. He W.Y. Wang H.B. Yang C.X. Curcumin ameliorated diabetic neuropathy partially by inhibition of NADPH oxidase mediating oxidative stress in the spinal cord. Neurosci. Lett. 2014 560 81 85 10.1016/j.neulet.2013.12.019 24370596
192 Hultqvist M. Bäcklund J. Bauer K. Gelderman K.A. Holmdahl R. Lack of reactive oxygen species breaks T cell tolerance to collagen type II and allows development of arthritis in mice. J. Immunol. 2007 179 3 1431 1437 10.4049/jimmunol.179.3.1431 17641008
193 Shin H.J. Park H. Shin N. Kwon H.H. Yin Y. Hwang J.A. Kim S.I. Kim S.R. Kim S. Joo Y. Kim Y. Kim J. Beom J. Kim D.W. p47phox siRNA-loaded PLGA nanoparticles suppress ROS/oxidative stress-induced chondrocyte damage in osteoarthritis. Polymers 2020 12 2 443 10.3390/polym12020443 32069893
194 Yin D.H. Liang X.C. Zhao L. Zhang H. Sun Q. Wang P.Y. Sun L.Q. Jinmaitong decreases sciatic nerve DNA oxidative damage and apoptosis in a streptozotocin-induced diabetic rat model. Exp. Ther. Med. 2015 10 2 778 786 10.3892/etm.2015.2543 26622393
195 Sandoval R. Lazcano P. Ferrari F. Pinto-Pardo N. González-Billault C. Utreras E. TNF-α increases production of reactive oxygen species through Cdk5 activation in nociceptive neurons. Front. Physiol. 2018 9 65 10.3389/fphys.2018.00065 29467671
196 Sun J. Chen F. Braun C. Zhou Y.Q. Rittner H. Tian Y.K. Cai X.Y. Ye D.W. Role of curcumin in the management of pathological pain. Phytomedicine 2018 48 129 140 10.1016/j.phymed.2018.04.045 30195871
197 Demaurex N. El Chemaly A. Physiological roles of voltage-gated proton channels in leukocytes. J. Physiol. 2010 588 23 4659 4665 10.1113/jphysiol.2010.194225 20693294
198 Peng J. Yi M.H. Jeong H. McEwan P.P. Zheng J. Wu G. Ganatra S. Ren Y. Richardson J.R. Oh S.B. Wu L.J. The voltage-gated proton channel Hv1 promotes microglia-astrocyte communication and neuropathic pain after peripheral nerve injury. Mol. Brain 2021 14 1 99 10.1186/s13041-021-00812-8 34183051
199 Zhang Q. Ren Y. Mo Y. Guo P. Liao P. Luo Y. Mu J. Chen Z. Zhang Y. Li Y. Yang L. Liao D. Fu J. Shen J. Huang W. Xu X. Guo Y. Mei L. Zuo Y. Liu J. Yang H. Jiang R. Inhibiting Hv1 channel in peripheral sensory neurons attenuates chronic inflammatory pain and opioid side effects. Cell Res. 2022 32 5 461 476 10.1038/s41422-022-00616-y 35115667
200 Wang Y. Li S.J. Wu X. Che Y. Li Q. Clinicopathological and biological significance of human voltage-gated proton channel Hv1 protein overexpression in breast cancer. J. Biol. Chem. 2012 287 17 13877 13888 10.1074/jbc.M112.345280 22367212
201 Shimizu S. Takahashi N. Mori Y. TRPs as chemosensors (ROS, RNS, RCS, gasotransmitters). Handb. Exp. Pharmacol. 2014 223 767 794 10.1007/978-3-319-05161-1_3 24961969
202 De Logu F. Li Puma S. Landini L. Portelli F. Innocenti A. de Araujo D.S.M. Janal M.N. Patacchini R. Bunnett N.W. Geppetti P. Nassini R. Schwann cells expressing nociceptive channel TRPA1 orchestrate ethanol-evoked neuropathic pain in mice. J. Clin. Invest. 2019 129 12 5424 5441 10.1172/JCI128022 31487269
203 Marone I.M. De Logu F. Nassini R. De Carvalho Goncalves M. Benemei S. Ferreira J. Jain P. Li Puma S. Bunnett N.W. Geppetti P. Materazzi S. TRPA1/NOX in the soma of trigeminal ganglion neurons mediates migraine-related pain of glyceryl trinitrate in mice. Brain 2018 141 8 2312 2328 10.1093/brain/awy177 29985973
204 De Logu F. De Siena G. Landini L. Marini M. Souza Monteiro de Araujo D. Albanese V. Preti D. Romitelli A. Chieca M. Titiz M. Iannone L.F. Geppetti P. Nassini R. Non-neuronal TRPA1 encodes mechanical allodynia associated with neurogenic inflammation and partial nerve injury in rats. Br. J. Pharmacol. 2022 36494916
205 Savio L.E.B. Leite-Aguiar R. Alves V.S. Coutinho-Silva R. Wyse A.T.S. Purinergic signaling in the modulation of redox biology. Redox Biol. 2021 47 102137 10.1016/j.redox.2021.102137 34563872
206 Chessell I.P. Hatcher J.P. Bountra C. Michel A.D. Hughes J.P. Green P. Egerton J. Murfin M. Richardson J. Peck W.L. Grahames C.B.A. Casula M.A. Yiangou Y. Birch R. Anand P. Buell G.N. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 2005 114 3 386 396 10.1016/j.pain.2005.01.002 15777864
207 Munoz F.M. Gao R. Tian Y. Henstenburg B.A. Barrett J.E. Hu H. Neuronal P2X7 receptor-induced reactive oxygen species production contributes to nociceptive behavior in mice. Sci. Rep. 2017 7 1 3539 10.1038/s41598-017-03813-7 28615626
208 Apolloni S. Parisi C. Pesaresi M.G. Rossi S. Carrì M.T. Cozzolino M. Volonté C. D’Ambrosi N. The NADPH oxidase pathway is dysregulated by the P2X7 receptor in the SOD1-G93A microglia model of amyotrophic lateral sclerosis. J. Immunol. 2013 190 10 5187 5195 10.4049/jimmunol.1203262 23589615
209 Qian Y. Xu S. Yang X. Xiao Q. Purinergic receptor P2Y6 contributes to 1-methyl-4-phenylpyridinium-induced oxidative stress and cell death in neuronal SH-SY5Y cells. J. Neurosci. Res. 2018 96 2 253 264 10.1002/jnr.24119 28752899
210 Wang Z. Zhao W. Shen X. Wan H. Yu J.M. The role of P2Y6 receptors in the maintenance of neuropathic pain and its improvement of oxidative stress in rats. J. Cell. Biochem. 2019 120 10 17123 17130 10.1002/jcb.28972 31106899
211 Cirillo G. Colangelo A.M. Berbenni M. Ippolito V.M. De Luca C. Verdesca F. Savarese L. Alberghina L. Maggio N. Papa M. Purinergic modulation of spinal neuroglial maladaptive plasticity following peripheral nerve injury. Mol. Neurobiol. 2015 52 3 1440 1457 10.1007/s12035-014-8943-y 25352445
212 Park H.S. Jung H.Y. Park E.Y. Kim J. Lee W.J. Bae Y.S. Cutting edge: Direct interaction of TLR4 with NAD(P)H oxidase 4 isozyme is essential for lipopolysaccharide-induced production of reactive oxygen species and activation of NF-kappa B. J. Immunol. 2004 173 6 3589 3593 10.4049/jimmunol.173.6.3589 15356101
213 Janciauskiene S. Vijayan V. Immenschuh S. TLR4 signaling by heme and the role of heme-binding blood proteins. Front. Immunol. 2020 11 1964 10.3389/fimmu.2020.01964 32983129
214 Lei J. Paul J. Wang Y. Gupta M. Vang D. Thompson S. Jha R. Nguyen J. Valverde Y. Lamarre Y. Jones M.K. Gupta K. Heme causes pain in sickle mice via toll-like receptor 4-mediated reactive oxygen species- and endoplasmic reticulum stress-induced glial activation. Antioxid. Redox Signal. 2021 34 4 279 293 10.1089/ars.2019.7913 32729340
215 Soh W.T. Zhang J. Hollenberg M.D. Vliagoftis H. Rothenberg M.E. Sokol C.L. Robinson C. Jacquet A. Protease allergens as initiators–regulators of allergic inflammation. Allergy 2023 78 5 1148 1168 10.1111/all.15678 36794967
216 Monnet F.P. Sigma-1 receptor as regulator of neuronal intracellular Ca2+: clinical and therapeutic relevance. Biol. Cell 2005 97 12 873 883 10.1042/BC20040149 16293108
217 Roh D.H. Kim H.W. Yoon S.Y. Seo H.S. Kwon Y.B. Kim K.W. Han H.J. Beitz A.J. Lee J.H. Intrathecal administration of sigma-1 receptor agonists facilitates nociception: Involvement of a protein kinase C-dependent pathway. J. Neurosci. Res. 2008 86 16 3644 3654 10.1002/jnr.21802 18655205
218 Dang P.M.C. Fontayne A. Hakim J. El Benna J. Périanin A. Protein kinase C zeta phosphorylates a subset of selective sites of the NADPH oxidase component p47phox and participates in formyl peptide-mediated neutrophil respiratory burst. J. Immunol. 2001 166 2 1206 1213 10.4049/jimmunol.166.2.1206 11145703
219 Choi S.R. Roh D.H. Yoon S.Y. Kang S.Y. Moon J.Y. Kwon S.G. Choi H.S. Han H.J. Beitz A.J. Oh S.B. Lee J.H. Spinal sigma-1 receptors activate NADPH oxidase 2 leading to the induction of pain hypersensitivity in mice and mechanical allodynia in neuropathic rats. Pharmacol. Res. 2013 74 56 67 10.1016/j.phrs.2013.05.004 23732704
220 Choi S.R. Kwon S.G. Choi H.S. Han H.J. Beitz A.J. Lee J.H. Neuronal NOS activates spinal NADPH oxidase 2 contributing to central sigma-1 receptor-induced pain hypersensitivity in mice. Biol. Pharm. Bull. 2016 39 12 1922 1931 10.1248/bpb.b16-00326 27601184
221 Roh D.H. Kim H.W. Yoon S.Y. Seo H.S. Kwon Y.B. Kim K.W. Han H.J. Beitz A.J. Na H.S. Lee J.H. Intrathecal injection of the sigma(1) receptor antagonist BD1047 blocks both mechanical allodynia and increases in spinal NR1 expression during the induction phase of rodent neuropathic pain. Anesthesiology 2008 109 5 879 889 10.1097/ALN.0b013e3181895a83 18946301
222 Schmitz J. Owyang A. Oldham E. Song Y. Murphy E. McClanahan T.K. Zurawski G. Moshrefi M. Qin J. Li X. Gorman D.M. Bazan J.F. Kastelein R.A. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005 23 5 479 490 10.1016/j.immuni.2005.09.015 16286016
223 Yin C. Liu B. Li Y. Li X. Wang J. Chen R. Tai Y. Shou Q. Wang P. Shao X. Liang Y. Zhou H. Mi W. Fang J. Liu B. IL-33/ST2 induces neutrophil-dependent reactive oxygen species production and mediates gout pain. Theranostics 2020 10 26 12189 12203 10.7150/thno.48028 33204337
224 Li Y. Li H. Han J. Sphingosine‐1‐phosphate receptor 2 modulates pain sensitivity by suppressing the ROS‐RUNX3 pathway in a rat model of neuropathy. J. Cell. Physiol. 2020 235 4 3864 3873 10.1002/jcp.29280 31603252
225 Levanon D. Bettoun D. Harris-Cerruti C. Woolf E. Negreanu V. Eilam R. Bernstein Y. Goldenberg D. Xiao C. Fliegauf M. Kremer E. Otto F. Brenner O. Lev-Tov A. Groner Y. The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons. EMBO J. 2002 21 13 3454 3463 10.1093/emboj/cdf370 12093746
226 Serafim K.G.G. Navarro S.A. Zarpelon A.C. Pinho-Ribeiro F.A. Fattori V. Cunha T.M. Alves-Filho J.C. Cunha F.Q. Casagrande R. Verri W.A. Jr Bosentan, a mixed endothelin receptor antagonist, inhibits superoxide anion-induced pain and inflammation in mice. Naunyn Schmiedebergs Arch. Pharmacol. 2015 388 11 1211 1221 10.1007/s00210-015-1160-z 26246053
227 Fattori V. Serafim K.G.G. Zarpelon A.C. Borghi S.M. Pinho-Ribeiro F.A. Alves-Filho J.C. Cunha T.M. Cunha F.Q. Casagrande R. Verri W.A. Jr Differential regulation of oxidative stress and cytokine production by endothelin ET A and ET B receptors in superoxide anion-induced inflammation and pain in mice. J. Drug Target. 2017 25 3 264 274 10.1080/1061186X.2016.1245308 27701898
228 Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009 136 2 215 233 10.1016/j.cell.2009.01.002 19167326
229 Im Y.B. Jee M.K. Choi J.I. Cho H.T. Kwon O.H. Kang S.K. Molecular targeting of NOX4 for neuropathic pain after traumatic injury of the spinal cord. Cell Death Dis. 2012 3 11 e426 10.1038/cddis.2012.168 23152062
230 López-González M.J. Landry M. Favereaux A. MicroRNA and chronic pain: From mechanisms to therapeutic potential. Pharmacol. Ther. 2017 180 1 15 10.1016/j.pharmthera.2017.06.001 28579386
231 Gambari R. Fabbri E. Borgatti M. Lampronti I. Finotti A. Brognara E. Bianchi N. Manicardi A. Marchelli R. Corradini R. Targeting microRNAs involved in human diseases: A novel approach for modification of gene expression and drug development. Biochem. Pharmacol. 2011 82 10 1416 1429 10.1016/j.bcp.2011.08.007 21864506
232 Boveris A. Oshino N. Chance B. The cellular production of hydrogen peroxide. Biochem. J. 1972 128 3 617 630 10.1042/bj1280617 4404507
233 Fransen M. Nordgren M. Wang B. Apanasets O. Role of peroxisomes in ROS/RNS-metabolism: Implications for human disease. Biochim. Biophys. Acta Mol. Basis Dis. 2012 1822 9 1363 1373 10.1016/j.bbadis.2011.12.001 22178243
234 De Duve C. Baudhuin P. Peroxisomes (microbodies and related particles). Physiol. Rev. 1966 46 2 323 357 10.1152/physrev.1966.46.2.323 5325972
235 Huang J.L. Chen X.L. Guo C. Wang Y.X. Contributions of spinal d-amino acid oxidase to bone cancer pain. Amino Acids 2012 43 5 1905 1918 10.1007/s00726-012-1390-z 22996731
236 Yamanaka M. Miyoshi Y. Ohide H. Hamase K. Konno R. d-Amino acids in the brain and mutant rodents lacking d-amino-acid oxidase activity. Amino Acids 2012 43 5 1811 1821 10.1007/s00726-012-1384-x 22892863
237 Ma S. Li X.Y. Gong N. Wang Y.X. Contributions of spinal d-amino acid oxidase to chronic morphine-induced hyperalgesia. J. Pharm. Biomed. Anal. 2015 116 131 138 10.1016/j.jpba.2015.03.021 25850373
238 Lu J.M. Gong N. Wang Y.C. Wang Y.X. D-Amino acid] oxidase-mediated increase in spinal hydrogen peroxide is mainly responsible for formalin-induced tonic pain. Br. J. Pharmacol. 2012 165 6 1941 1955 10.1111/j.1476-5381.2011.01680.x 21950354
239 Zhao W.J. Gao Z.Y. Wei H. Nie H.Z. Zhao Q. Zhou X.J. Wang Y.X. Spinal D-amino acid oxidase contributes to neuropathic pain in rats. J. Pharmacol. Exp. Ther. 2010 332 1 248 254 10.1124/jpet.109.158816 19828879
240 Wei H. Gong N. Huang J.L. Fan H. Ma A.N. Li X.Y. Wang Y.X. Pertovaara A. Spinal D-amino acid oxidase contributes to mechanical pain hypersensitivity induced by sleep deprivation in the rat. Pharmacol. Biochem. Behav. 2013 111 30 36 10.1016/j.pbb.2013.08.003 23958579
241 Gong N. Li X.Y. Xiao Q. Wang Y.X. Identification of a novel spinal dorsal horn astroglial D-amino acid oxidase-hydrogen peroxide pathway involved in morphine antinociceptive tolerance. Anesthesiology 2014 120 4 962 975 10.1097/ALN.0b013e3182a66d2a 23928652
242 Zhao W. Konno R. Zhou X.J. Yin M. Wang Y.X. Inhibition of D-amino-Acid oxidase activity induces pain relief in mice. Cell. Mol. Neurobiol. 2008 28 4 581 591 10.1007/s10571-007-9200-y 17874293
243 Hopkins S.C. Zhao F.Y. Bowen C.A. Fang X. Wei H. Heffernan M.L.R. Spear K.L. Spanswick D.C. Varney M.A. Large T.H. Pharmacodynamic effects of a D-amino acid oxidase inhibitor indicate a spinal site of action in rat models of neuropathic pain. J. Pharmacol. Exp. Ther. 2013 345 3 502 511 10.1124/jpet.113.204016 23520265
244 Wake K. Yamazaki H. Hanzawa S. Konno R. Sakio H. Niwa A. Hori Y. Exaggerated responses to chronic nociceptive stimuli and enhancement of N-methyl-d-aspartate receptor-mediated synaptic transmission in mutant mice lacking d-amino-acid oxidase. Neurosci. Lett. 2001 297 1 25 28 10.1016/S0304-3940(00)01658-X 11114476
245 Choi S.R. Moon J.Y. Roh D.H. Yoon S.Y. Kwon S.G. Choi H.S. Kang S.Y. Han H.J. Beitz A.J. Lee J.H. Spinal D-serine increases PKC-dependent GluN1 phosphorylation contributing to the sigma-1 receptor-induced development of mechanical allodynia in a mouse model of neuropathic pain. J. Pain 2017 18 4 415 427 10.1016/j.jpain.2016.12.002 27986591
246 Dieb W. Hafidi A. Astrocytes are involved in trigeminal dynamic mechanical allodynia: potential role of D-serine. J. Dent. Res. 2013 92 9 808 813 10.1177/0022034513498898 23881719
247 Mothet J.P. Parent A.T. Wolosker H. Brady R.O. Jr Linden D.J. Ferris C.D. Rogawski M.A. Snyder S.H. D -Serine is an endogenous ligand for the glycine site of the N -methyl- D -aspartate receptor. Proc. Natl. Acad. Sci. USA 2000 97 9 4926 4931 10.1073/pnas.97.9.4926 10781100
248 Inoguchi T. Nawata H. NAD(P)H oxidase activation: A potential target mechanism for diabetic vascular complications, progressive beta-cell dysfunction and metabolic syndrome. Curr. Drug Targets 2005 6 4 495 501 10.2174/1389450054021927 16026268
249 Pushpakom S. Iorio F. Eyers P.A. Escott K.J. Hopper S. Wells A. Doig A. Guilliams T. Latimer J. McNamee C. Norris A. Sanseau P. Cavalla D. Pirmohamed M. Drug repurposing: Progress, challenges and recommendations. Nat. Rev. Drug Discov. 2019 18 1 41 58 10.1038/nrd.2018.168 30310233
250 Wilkaniec A. Cieślik M. Murawska E. Babiec L. Gąssowska-Dobrowolska M. Pałasz E. Jęśko H. Adamczyk A. P2X7 receptor is involved in mitochondrial dysfunction induced by extracellular alpha synuclein in neuroblastoma SH-SY5Y Cells. Int. J. Mol. Sci. 2020 21 11 3959 10.3390/ijms21113959 32486485
251 Ushio-Fukai M. Compartmentalization of redox signaling through NADPH oxidase-derived ROS. Antioxid. Redox Signal. 2009 11 6 1289 1299 10.1089/ars.2008.2333 18999986
